Conditions: Healthy Participants
Keywords: Drug-drug interaction Midazolam COVID-19 (Coronavirus disease 2019) SARS-CoV (severe acute respiratory syndrome coronavirus)
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 12
Healthy volunteers: yes

Brief summary:
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 \[CYP\]3A4 substrate) in Healthy Adult Participants.

Detailed description:

Arms:
arm 1: Midazolam orally arm 2: PF-07321332/ritonavir orally + Midazolam orally arm 3: Ritonavir orally + Midazolam orally

Interventions: intervention 1: Midazolam intervention 2: PF-07321332/ritonavir + Midazolam intervention 3: Ritonavir + Midazolam
Intervention descriptions: intervention 1: Midazolam administered as a single dose on Day 1 intervention 2: PF-07321332/ritonavir:

Administered orally every 12 hours for a total of 9 doses on Days 1-5

Midazolam:

Administered orally as a single dose on Day 5 intervention 3: Ritonavir:

Administered orally every 12 hours for a total of 9 doses on Day1-5.

Midazolam:

Administered orally as a single dose on Day 5

Protocol document:
Prot_000.pdf: 
P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 1
C O VI D -1 9: A P H A S E 1, O P E N -L A B E L, 3- T R E A T M E N T, 6- S E Q U E N C E, 3 -P E RI O D
C R O S S O V E R S T U D Y T O E S TI M A T E T H E E F F E C T O F P F -0 7 3 2 1 3 3 2/ RI T O N A VI R 
A N D RI T O N A VI R O N T H E P H A R M A C O KI N E T I C S O F MI D A Z O L A M I N 
H E A L T H Y P A R TI CI P A N T S
St u d y I nter ve nti o n N u m ber :
P F -0 7 3 2 1 3 3 2
St u d y I nter ve nti o n N a me:
N/ A
U S I N D N u m ber:
E u dr a C T N u m ber:
2 0 2 1 -0 0 3 5 9 0 -6 2
Cli nic al Tri als. g o v I D:
N/ A
Pr ot oc ol N u m ber:
C 4 6 7 1 0 1 3
P h ase:
1
Brief Title: A P hase 1 St u d y  t o Esti mate t he Effect of P F -0 7 3 2 1 3 3 2/ Rit o na vir a n d
Rit o na vir o n t he P K of Mi daz ola m i n Healt h y  Partici pa nts
T his d oc u me nt a n d acc o m pa n yi n g materials c o ntai n c o nfi de ntial i nf or mati o n bel o n gi n g t o Pfizer. E xce pt as 
ot her wise a gree d t o i n writi n g, b y acce pti n g or re vie wi n g t hese d oc u me nt s, yo u a gree t o h ol d t his 
i nf or mati o n i n c o nfi de nce a n d n ot c o p y or discl ose it t o ot hers (e xce pt w here re q uire d b y a p plica ble la w) or 
use it f or u na ut h orize d p ur p oses. I n t he e ve nt of a n y act ual or s us pecte d breac h of t his o bli gati o n, Pfizer 
m ust be pr o m ptl y n otifie d.
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 2
Document History
Document
Version Date
Original protocol
23 July 2021


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 3
T A B L E O F C O N T E N T S
LI S T O F T A B L E S .....................................................................................................................7
1. P R O T O C O L  S U M M A R Y..................................................................................................... 8
1. 1. S y n o psis .................................................................................................................... 8
1. 2. Sc he ma .................................................................................................................... 1 1
1. 3. Sc he d ule of Acti vities ............................................................................................. 1 2
2. I N T R O D U C TI O N ............................................................................................................... 1 9
2. 1. St u d y  Rati o nale ....................................................................................................... 1 9
2. 2. Bac k gr o u n d ............................................................................................................. 1 9
2. 2. 1. N o ncli nical P har mac ol o g y .......................................................................... 1 9
2. 2. 2. N o ncli nical P har mac o ki netics a n d Meta b olis m ......................................... 1 9
2. 2. 3. N o ncli nical Safet y ...................................................................................... 2 0
2. 2. 4. Cli nical O ver vie w ....................................................................................... 2 0
2. 3. Be nefit/ Ris k Assess me nt ......................................................................................... 2 2
2. 3. 1. Ris k Assess me nt ......................................................................................... 2 3
2. 3. 2. Be nefit Assess me nt ..................................................................................... 2 6
2. 3. 3. O verall Be nefit/ Ris k C o ncl usi o n ................................................................ 2 6
3. O BJ E C TI V E S A N D E N D P OI N T S ..................................................................................... 2 6
4. S T U D Y D E SI G N ................................................................................................................. 2 7
4. 1. O verall Desi g n ......................................................................................................... 2 7
4. 2. Scie ntific Rati o nale f or St u d y  Desi g n..................................................................... 2 8
4. 2. 1. C h oice of C o ntrace pti o n/ Barrier Re q uire me nts ......................................... 2 8
4. 2. 2. C ollecti o n of Retai ne d Researc h Sa m ples .................................................. 2 8
4. 3. J ustificati o n f or D ose ..............................................................................................2 9
4. 4. E n d of St u d y  Defi niti o n .......................................................................................... 2 9
5. S T U D Y P O P U L A T I ON ......................................................................................................2 9
5. 1. I ncl usi o n Criteria ..................................................................................................... 2 9
5. 2. E xcl u si o n Criteria.................................................................................................... 3 0
5. 3. L ifest yle C o nsi derati o ns.......................................................................................... 3 3
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 4
5.3.1. Meals and Dietary Restrictions...................................................................33
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................34
5.3.3. Activity .......................................................................................................34
5.3.4. Contraception..............................................................................................34
5.4. Screen Failures ........................................................................................................34
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY.................................35
6.1. Study Intervention(s) Administered........................................................................35
6.1.1. Administration............................................................................................35
6.2. Preparation, Handling, Storage, and Accountability...............................................36
6.2.1. Preparation and Dispensing........................................................................37
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................38
6.3.1. Allocation to Study Intervention ................................................................38
6.4. Study Intervention Compliance...............................................................................38
6.5. Dose Modification...................................................................................................38
6.6. Continued Access to Study Intervention After the End of the Study......................38
6.7. Treatment of Overdose............................................................................................38
6.8. Concomitant Therapy..............................................................................................39
6.8.1. Rescue Medicine.........................................................................................39
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL...........................................................................39
7.1. Discontinuation of Study Intervention ....................................................................39
7.1.1. ECG Changes..............................................................................................40
7.1.2. Potential Cases of Acute Kidney Injury .....................................................40
7.1.3. Stopping Rules............................................................................................41
7.2. Participant Discontinuation/Withdrawal From the Study.......................................41
7.2.1. Withdrawal of Consent...............................................................................42
7.3. Lost to Follow-up....................................................................................................42
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................43
8.1. Efficacy Assessments..............................................................................................44
8.2. Safety Assessments .................................................................................................44
8.2.1. Physical Examinations................................................................................44
8.2.2. Vital Signs ..................................................................................................44


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5
8. 2. 2. 1. Res pi rat or y Rate........................................................................ 4 5
8. 2. 2. 2. Te m perat ure .............................................................................. 4 5
8. 2. 3. Electr ocar di o gra ms ..................................................................................... 4 5
8. 2. 4. Cli nical Safet y  La b orat or y Assess me nts.................................................... 4 6
8. 2. 5. C O VI D -1 9 s pecific assess me nts ................................................................. 4 7
8. 2. 6. Pre g na nc y  Testi n g ...................................................................................... 4 7
8. 3. A d verse E ve nts, Seri o us A d verse E ve nts, a n d Ot her Safet y Re p orti n g ................. 4 7
8. 3. 1. Ti me Peri o d a n d Fre q ue nc y  f or C ollecti n g A E a n d S A E I nf or mati o n....... 4 7
8. 3. 1. 1. Re p orti n g S A Es t o Pfizer Safet y ............................................... 4 8
8. 3. 1. 2. Rec or di n g N o nseri o us A Es a n d S A Es o n t he C R F ................... 4 8
8. 3. 2. Met h o d of Detecti n g A Es a n d S A Es .......................................................... 4 9
8. 3. 3. F oll o w -U p of A Es a n d S A Es ...................................................................... 4 9
8. 3. 4. Re g ulat or y  Re p orti n g Re q uire me nts f or S A Es........................................... 4 9
8. 3. 5. E n vir o n me ntal E x p os ure, E x p os ure D uri n g Pre g na nc y  or 
Breastfee di n g, a n d Occ u pati o nal E x p os ure ..................................................... 4 9
8. 3. 5. 1. E x p os ure D uri n g Pre g na nc y...................................................... 5 0
8. 3. 5. 2. E x p os ure D uri n g Breastfee di n g ................................................ 5 1
8. 3. 5. 3. Occ u pati o nal E x p os ure ............................................................. 5 2
8. 3. 6. Car di o vasc ular a n d Deat h E ve nts ...............................................................5 2
8. 3. 7. Disease -Relate d E ve nts a n d/ or Disease - Relate d O utc o mes N ot 
Q ualif yi n g as A Es or S A Es .............................................................................. 5 2
8. 3. 8. A d verse E ve nts of S peci al I nterest ............................................................. 5 2
8. 3. 8. 1. Lac k of Efficac y ........................................................................ 5 2
8. 3. 9. Me dical De vice Deficie ncies ......................................................................5 2
8. 3. 1 0. Me dicati o n Err ors ..................................................................................... 5 3
8. 4. P har mac o ki netics .................................................................................................... 5 3
8. 6. Bi o mar kers .............................................................................................................. 5 5
8. 6. 1. S pecifie d Ge ne E x pressi o n ( R N A) Researc h .............................................5 5
8. 6. 2. S pecifie d Pr otei n Researc h ......................................................................... 5 5
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 6
8. 6. 3. S pecifie d Meta b ol o mic Researc h ...............................................................5 5
8. 7. I m m u n o ge nicit y Assess me nts ................................................................................. 5 5
8. 8. Healt h Ec o n o mics ................................................................................................... 5 6
9. S T A TI S TI C A L C O N SI D E R A TI O N S ................................................................................ 5 6
9. 1. Statistical H y p ot heses ............................................................................................. 5 6
9. 2. A nal y sis Sets ........................................................................................................... 5 6
9. 3. Statistical A nal y ses ................................................................................................. 5 6
9. 3. 1. P har mac o ki netic A nal y ses .......................................................................... 5 7
9. 3. 1. 1. Deri vati o n of P har mac o ki netic Para meters ...............................5 7
9. 3. 2. Pri mar y  E n d p oi nt(s).................................................................................... 5 8
9. 3. 3. Sec o n dar y  E n d p oi nt(s)................................................................................ 5 8
9. 3. 5. Ot her Safet y A nal yses ................................................................................ 5 8
9. 3. 6. Ot her A nal ys e(s) ......................................................................................... 5 8
9. 4. I nteri m A nal ys es ..................................................................................................... 5 9
9. 5. Sa m ple Size Deter mi nati o n ..................................................................................... 5 9
1 0. S U P P O R TI N G D O C U M E N T A TI O N A N D O P E R A TI O N A L 
C O N SI D E R A TI O N S.......................................................................................................... 6 0
1 0. 1. A p pe n di x 1: Re g ulat or y , Et hical, a n d St u d y O versi g ht C o nsi derati o ns............... 6 0
1 0. 1. 1. Re g ulat or y a n d Et hical C o nsi derati o ns .................................................... 6 0
1 0. 1. 1. 1. Re p orti n g of Safet y  Iss ues a n d Seri o us Breac hes of t he 
Pr ot oc ol or I C H G C P ......................................................................... 6 0
1 0. 1. 2. I nf or me d C o nse nt Pr ocess ........................................................................6 1
1 0. 1. 3. Data Pr otecti o n ......................................................................................... 6 2
1 0. 1. 4. C o m mittees Str uct ure ............................................................................... 6 2
1 0. 1. 4. 1. Data M o nit ori n g C o m mittee ................................................... 6 2
1 0. 1. 5. Disse mi nati o n of Cli nical St u d y  Data ...................................................... 6 2
1 0. 1. 6. Data Q ualit y Ass ura nce ............................................................................ 6 3
1 0. 1. 7. S o urce D oc u me nts ....................................................................................6 4
1 0. 1. 8. St u d y  a n d Site Start a n d Cl os ure ..............................................................6 5
1 0. 1. 9. P u blicati o n P olic y..................................................................................... 6 6
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 7
1 0. 1. 1 0. S p o ns or’s Q ualifie d Me dical Pers o n nel .................................................6 6
1 0. 2. A p pe n di x 2: Cli nical La b orat or y  Tests................................................................. 6 8
1 0. 3. A p pe n di x 3: A d verse E ve nts: Defi niti o ns a n d Pr oce d ures f or Rec or di n g, 
E val uati n g, F oll o w -U p, a n d Re p orti n g ..................................................................... 6 9
1 0. 3. 1. Defi niti o n of A E ....................................................................................... 6 9
1 0. 3. 2. Defi niti o n of a n S A E ................................................................................ 7 0
1 0. 3. 3. Rec or di n g/ Re p orti n g a n d F oll o w -U p of A Es a n d/ or S A Es D uri n g 
t he Acti ve C ollecti o n Peri o d............................................................................ 7 1
1 0. 3. 4. Re p orti n g of S A Es .................................................................................... 7 5
1 0. 4. A p pe n di x 4: C o ntrace pti ve a n d Barrier G ui da nce ................................................ 7 6
1 0. 4. 1. Male Partici pa nt Re pr o d ucti ve I ncl usi o n Criteria .................................... 7 6
1 0. 4. 2. Fe male Partici pa nt Re pr o d ucti ve I ncl usi o n Cr iteria................................. 7 6
1 0. 4. 3. W o ma n of C hil d beari n g P ote ntial ............................................................ 7 7
1 0. 4. 4. C o ntrace pti o n Met h o ds ............................................................................. 7 8
1 0. 6. A p pe n di x 6: L i ver Safet y: S u g geste d Acti o ns a n d F oll o w-U p Assess me nts ....... 8 0
1 0. 7. A p pe n di x 7: E C G Fi n di n gs of P ote ntial Cli nical C o ncer n ................................... 8 2
1 0. 8. A p pe n di x 8: A b bre viati o ns ................................................................................... 8 4
1 1. R E F E R E N C E S .................................................................................................................. 8 8
LI S T O F T A B L E S
Ta ble 1.
Treat me nt Se q ue nces ................................................................................ 2 8
Ta ble 2.
Pr ot oc ol -Re q uire d Safet y L a b orat or y Assess me nts ................................. 6 8
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 8
1. P R O T O C O L S U M M A R Y 
1. 1. S y n o psis 
Brief Title: A P hase 1 St u d y  t o Esti mate t he Effect of P F - 0 7 3 2 1 3 3 2/ Rit o na vir a n d Rit o na vir 
o n t he P K of Mi daz ola m i n Healt h y  Partici pa nts
R ati o n ale : T his is a P hase 1, o pe n -la bel st u d y t o e val uate t he effect of stea d y-state 
P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n t he P K of mi daz ola m i n healt h y  a d ult partici pa nts. 
P F -0 7 3 2 1 3 3 2 was e xa mi ne d f or i n vitr o i n hi biti o n of t he maj or C Y P a n d U G T e nz y mes, 
i n d ucti o n of t he maj or C Y P e nz ymes, a n d i n hi biti o n of vari o us effl u x, he patic u pta ke, a n d 
re nal tra ns p orters. Res ults s u g gest t hat P F -0 7 3 2 1 3 3 2 is li kel y t o re versi bl y a n d 
ti me-de pe n de ntl y i n hi bit C Y P 3 A 4 at t he pr o p o se d t hera pe utic d ose. R it o na vir is a p ote nt
i n hi bit or of C Y P 3 A. A d diti ve D DI ris k is p ossi ble fr o m P F- 0 7 3 2 1 3 3 2/rit o na vir b e y o n d w hat 
is p ose d b y rit o na vir al o ne.
T he p ur p ose of t his st u d y is t o esti mate t he effect of P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n 
t he P K of a C Y P 3 A 4 s u bstrate, mi daz ola m, i n healt h y partici pa nts.
O bjecti ves a n d E n d p oi nts
O bjecti ves
E n d p oi nts
Pri m ar y O bjecti ve: 
Pri m ar y E n d p oi nt: 

T o esti mate t he effect of P F -0 7 3 2 1 3 3 2/rit o na vir 
o n t he P K of mi daz ola m

Mi daz ola m plas ma P K para meters: C
ma x a n d 
A U C i nf (if data per mit , ot her wise A U Clast) wit h 
P F -0 7 3 2 1 3 3 2/rit o na vir (test) vers us wit h o ut 
P F -0 7 3 2 1 3 3 2/rit o na vir (refere nce)
Sec o n d ar y O bjecti ve: 
Sec o n d ar y E n d p oi nts: 

T o e val uate t he safet y a n d t olera bilit y of 
P F -0 7 3 2 1 3 3 2/rit o na vir i n healt h y partici pa nts i n 
t he a bse nce a n d prese nce of mi daz ola m

T o esti mate t he effect of rit o na vir o n t he P K of 
mi daz ola m

T o e val uate t he effects of P F- 0 7 3 2 1 3 3 2 /rit o na vir
a n d rit o na vir o n a d diti o nal P K para meters of 
mi daz ola m i n healt h y partici pa nts

Assess me nt of T E A E s, cli nical la b orat or y 
a b n or malities, vital si g ns , a n d 1 2 -lea d E C Gs

Mi daz ola m plas ma P K para meters: C ma x a n d 
A U C i nf (if data per mit , ot her wise A U Clast) wit h 
rit o na vir (test) vers us wit h o ut rit o na vir 
(refere nce)

Mi daz ola m
plas ma P K para meters: T ma x , t½ , 
A U C last, C L/ F, a n d Vz/ F f or mi daz ola m wit h 
a n d wit h o ut c oa d mi nistrati o n of 
P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir
C CI
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 9
O ver all Desi g n
Brief S u m m ar y
T his is a P hase 1, o pe n -la bel, 3-treat me nt, 6-se q ue nce, 3-peri o d cr oss o ver st u d y  t o esti mate
t he effect of stea dy- state P F-0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n t he P K of mi daz ola m i n 
healt h y  a d ult partici pa nts. T he st u d y  will c o nsist of 3 treat me nts: si n gle oral d ose of 2 m g 
mi daz ola m al o ne ( Treat me nt A) , m ulti ple oral d oses of 3 0 0 m g P F -0 7 3 2 1 3 3 2 / 1 0 0 m g 
rit o na vir i n c o m bi nati o n wit h a si n gle oral d ose of 2 m g mi daz ola m ( Treat me nt B ), a n d 
m ulti ple oral d oses of 1 0 0 m g rit o na vir i n c o m bi nati o n wit h a si n gle oral d ose of 2 m g
mi daz ola m ( Treat me nt C). T he treat me nt will c o nsist of 6 treat me nt se q ue nces s h o w n i n t he 
ta ble bel o w, wit h eac h partici pa nt recei vi n g all 3 treat me nts, acc or di n g t o t he assi g ne d 
se q ue nce o ver 3 peri o d s. 
A t otal of a p pr o xi matel y  1 2 healt h y  male a n d/ or fe male partici pa nts will be e nr olle d i nt o t he 
st u d y t o e ns ure at least 1 0 partici pa nts will c o m plete t he st u d y . Partici pa nts w h o disc o nti n ue d 
fr o m t he st u d y f or n o n-safet y reas o ns ma y be re place d at t he s p o ns or’s discreti o n i n 
c olla b orati o n wit h t he i n vesti gat or. 
N u m ber of P artici p a nts
A p pr o xi matel y  1 2 partici pa nts will be ra n d o ml y  assi g ne d t o 1 of 6 trea tme nt se q ue nces.
N ote: " E nr olle d" mea ns a partici pa nt's, or hi s or her le gall y a ut h orize d re prese ntati ve’s, 
a gree me nt t o partici pate i n a cli nical st u d y  f oll o wi n g c o m pleti o n of t he i nf or me d c o nse nt 
pr ocess a n d scree ni n g. A partici pa nt will be c o nsi dere d e nr olle d if t he i nf or me d c o nse nt is 
n ot wit h dra w n pri or t o parti ci pati n g i n a n y st u d y acti vit y  after scree ni n g. P ote ntial 
partici pa nts w h o are scree ne d f or t he p ur p ose of deter mi ni n g eli gi bilit y  f or t he st u d y, b ut d o 
n ot partici pate i n t he st u d y, are n ot c o nsi dere d e nr olle d, u nless ot her wise s pecifie d b y t he 
pr ot oc ol.
I nter ve nti o n Gr o u ps a n d D ur ati o n
Eac h partici pa nt will be scree ne d t o deter mi ne eli gi bilit y  wit hi n 2 8 d a y s pri or t o st u d y 
treat me nt. Eli gi ble partici pa nts will re p ort t o t he C R U o n Da y -1 a n d will be re q uire d t o sta y  
i n t he C R U f or 2 8 d a y s a n d 2 7 ni g hts. A safety f oll o w - u p call will be ma de t o partici pa nts 
a p pr o xi matel y 2 8 t o 3 5 da ys fr o m a d mi nistrati o n of t he fi nal d ose of st u d y i nter ve nti o n. 
Eac h e nr olle d partici pa nt will partici pate i n 3 st u d y peri o ds t o recei ve 3 differe nt treat me nts
acc or di n g t o t he se q ue nce deter mi ne d b y ra n d o mizati o n: 

Treat me nt A: Si n gle oral d ose of 2 m g mi daz ola m .
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 10

Treatment B: 300 mg PF-07321332/100 mg ritonavir administered orally, q12h for 
9 doses: Day 1 morning to Day 5 morning. On Day 5, participants will receive a 
single oral dose of 2 mg midazolam administered with the Day 5 morning dose of 
PF-07321332/ritonavir.

Treatment C: 100 mg ritonavir administered orally, q12h for 9 doses: Day 1 morning 
to Day 5 morning. On Day 5, participants will receive a single oral dose of 2 mg 
midazolam administered with the Day 5 morning dose of ritonavir.
Participants will be randomly assigned to 1 of 6 sequences as follows: 
Period 1
Period 2
Period 3
Sequence 1
Treatment A
Treatment B
Treatment C
Sequence 2
Treatment C
Treatment A
Treatment B
Sequence 3
Treatment B
Treatment C
Treatment A
Sequence 4
Treatment C
Treatment B
Treatment A
Sequence 5
Treatment B
Treatment A
Treatment C
Sequence 6
Treatment A
Treatment C
Treatment B
Participants will be discharged on Period 3, following completion of all assessments. 
The total planned duration of participation, from the Screening visit to the last Follow-up
phone call, is approximately 13 weeks.
Data Monitoring Committee or Other Independent Oversight Committee: No
Statistical Methods
Natural log transformed AUCinf (if data permit), AUClast and Cmax will be analyzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect. Estimates of the adjusted mean differences 
(Test-Reference) and corresponding 90% confidence intervals will be obtained from the 
model. The adjusted mean differences and 90% confidence intervals for the differences will 
be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and 90% confidence intervals for the ratios. Midazolam alone is the 
Reference treatment whilst midazolam + PF-07321332/ritonavir and midazolam + ritonavir 
are the Test treatments.
A sample size of 12 participants (2 per sequence) will provide 90% confidence intervals for 
the difference between treatments of ±0.1650 on the natural log scale for AUCinf
(midazolam) with 80% coverage probability. The following table presents the width of 
90% CI for different estimated effects:


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 11
Parameter
Estimated Effect
(100*Test/Reference)
90% CI
CI Width
AUCinf
80%
67.83%, 94.35%
26.52%
90%
76.32%, 106.14%
29.83%
100%
84.79%, 117.94%
33.14%
150%
127.19%, 176.90%
49.72%
200%
169.58%, 235.87%
66.29%
250%
211.98%, 294.84%
82.86%
300%
254.38%, 353.81%
99.43%
400%
339.17%, 471.74%
132.58%
These calculations are based on estimates of within‑participant coefficient of variation of 
19.41% for loge AUCinf (midazolam), as obtained from the Pfizer Clinical Pharmacology 
Guidance.
1.2. Schema


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 1 2
1. 3. S c he d ule of Acti v ities
T he S o A ta ble pr o vi des a n o ver vie w of t he pr ot oc ol visits a n d pr oce d ures. Refer t o t he S T U D Y A S S E S S M E N T S A N D 
P R O C E D U R E S secti o n of t he pr ot oc ol f or detaile d i nf or mati o n o n eac h pr oce d ure a n d assess me nt re q uire d f or c o m plia nce wit h t he 
pr ot oc ol. 
T he i n vesti gat or ma y  sc hed ule visits ( u n pla n ne d visits) i n a d diti o n t o t h ose liste d in t he S o A ta ble, i n or der t o c o n d uct e val uati o ns or 
assess me nts re q uire d t o pr otect t he well -bei n g of t he partici pa nt .
Visit I de ntifiera
A b bre viati o ns use d i n t his ta ble ma y 
be f o u n d i n A p pe n di x 8 .
Scree ni n g b
Tre at me nt ( See Det aile d S o A f or E ac h Tre at me nt)
F oll o w -U p 
E arl y 
Ter mi n ati o n/
Disc o nti n u ati o n
D a ys Rel ati ve t o D a y 1 of Peri o d 1
D a y -2 8 t o 
D a y - 2
D a y - 1
D a y 2 7 a
2 8 -3 5 D a ys c
H o urs After D ose
I nf or me d c o nse nt
X
C R U c o nfi ne me nt d
X
 
 
 
 
 
 

X
I ncl usi o n/e xcl usi o n criteria
X
X
Me dical/ me dicati o n hist or y ( u p date)
e
X
X
P h ysical e xa m i nati o nf
X
X
X
Safet y la b orat or y g
X
X
X
T S H & Free T 4
X
X
De m o gra p h y h
X
Pre g na nc y test ( W O C B P o nl y)
X
X
X
X
C o ntrace pti o n c hec k i
X
X
X
X
X
F S H j
X
Uri ne dr u g testi n g k
X
X
1 2 -Lea d E C G l
X
X
Vital si g ns ( B P/ P R/ R R) m
X
X
HI V, H Bs A g, H Bs A b, H Bc A b,
H C V A b 
X
C O VI D -1 9 q uesti o n naire n
X
X
C O VI D -1 9 testi n g o
X
X
C O VI D -1 9 c hec k te m perat ure p
X
X
X
X
X
St u d y i nter ve nti o n a d mi nistrati o n
P K bl o o d sa m pli n g 
X
Bl o o d/ Plas ma rati o sa m ple 
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 1 3
Visit I de ntifiera
A b bre viati o ns use d i n t his ta ble ma y 
be f o u n d i n A p pe n di x 8 .
Scree ni n g b
Tre at me nt ( See Det aile d S o A f or E ac h Tre at me nt)
F oll o w -U p 
E arl y 
Ter mi n ati o n/
Disc o nti n u ati o n
D a ys Rel ati ve t o D a y 1 of Peri o d 1
D a y -2 8 t o 
D a y - 2
D a y - 1
D a y 2 7 a
2 8 -3 5 D a ys c
H o urs After D ose
C R U disc har ge 
X
Seri o us a n d n o nseri o us A E 
m o nit ori n g
X
 
 
 
 
 
 
 
 



a.
Da y relati ve t o start of st u d y i nter ve nti o n ( Peri o d 1, Da y 1) ; St u d y Da y 2 7 will occ ur o n t he last da y of Peri o d 3 (e g , Peri o d 3, Da y 3 f or Treat me nt A , or Peri o d 1 or Peri o d 
2, Da y 1 2 f or Treat me nt B a n d Treat me nt C).
b.
Scree ni n g will be perf or me d wit hi n 2 8 da ys pri or t o t he first d ose of st u d y i nter ve nti o n. 
c.
C o ntact ma y occ ur via tele p h o ne c o ntact a n d m ust occ ur 2 8 t o 3 5 da ys fr o m a d mi nistrati o n of t he fi nal d ose of st u d y i nter ve nti o n.
d.
Partici pa nts will be a d mitte d t o t he C R U o n Da y -1. Partici pa nts will be disc har ge d o n Da y 2 7 f oll o wi n g t he fi nal assess me nts. 
e.
Me dical hist or y will i ncl u de a
hist or y of pri or ille gal dr u g, alc o h ol, a n d t o bacc o use, as well as bl o o d d o nati o n wit hi n pri or 6 0 da ys. Me dical hist or y will be rec or de d at 
Scree ni n g a n d u p date d o n Da y -1 of Peri o d 1. 
f.
A P E will be perf or me d b y trai ne d me dical pers o n nel at t he i n vesti gat or site at Scree ni n g or Da y -1 of Peri o d 1 o nl y ( hei g ht a n d wei g ht m ust be o btai ne d at Scree ni n g t o 
o btai n B MI f or eli gi bilit y criteria) a n d at Earl y Ter mi nati o n/ Disc o nti n uati o n . A brief P E ma y be perf or me d at ot her desi g nate d ti me p oi nts at t he discreti o n of t he 
i n vesti gat or. 
g.
Safet y la b orat or y assess me nts i ncl u di n g uri nal ysis, he mat ol o g y, c he mistr y a n d c oa g ulati o n will be perf or me d at t he i n dicate d ti me p oi nts. All t he safet y la b orat or y sa m ples 
m ust be c ollecte d f oll o wi n g at least a 4- h o ur fast. A d diti o nal safet y la b orat or y assess me nts ma y be perf or me d at a n y ti me at t he discreti o n of t he i n vesti gat or. 
h.
De m o gra p hics will i ncl u de partici pa nt race, et h nicit y, a ge, a n d ge n der d uri n g t he Scre e ni n g visit. 
i.
T he i n vesti gat or or his/ her desi g nee will disc uss wit h t he partici pa nt t he nee d t o use hi g hl y effecti ve c o ntrace pti o n c o nsist e ntl y a n d c orrectl y acc or di n g t o c o ntrace pti o n 
g ui deli nes.
j.
F or p ost me n o pa usal (a me n orr heic f or at least 1 2 c o nsec uti ve m o nt hs) fe male partici pa nts o nl y.
k.
Uri ne dr u g ( ma n dat or y) a n d alc o h ol breat h test (at discreti o n of i n vesti gat or) will be perf or me d at Scree ni n g a n d o n Da y -1. T hese tests ma y be perf or me d at a n y ot her ti me 
at t he discreti o n of t he i n vesti gat or.
l.
Tri plicate 1 2 -lea d E C G rea di n gs a p pr o xi matel y 2 mi n utes a part will be ta ke n at s pecifie d ti mes. All E C G assess me nts will be ma de after at least a 5 - mi n ute rest i n a s u pi ne 
p ositi o n a n d pri or t o a n y bl o o d dra ws or vital si g n meas ure me nts. 
m.
Si n gle s u pi ne B P , R R a n d P R will be perf or me d f oll o wi n g at least a 5-mi n ute rest i n a s u pi ne p ositi o n. B P, R R a n d P R assess me nts will be perf or me d after c ollecti o n of 
E C Gs a n d pri or t o c ollecti o n of bl o o d dra ws if sc he d ule d at t he sa me ti me.
n.
C hec k e x p os ure t o p ositi ve s u b ject, resi de nce or tra vel i n area of hi g h i nci de nce a n d C O VI D-1 9 relate d si g ns a n d s y m pt o ms. T o be d o ne wit hi n 7 2 h o urs bef ore a n d at eac h 
visit.
o.
T he testi n g f or C O VI D -1 9 pat h o ge n b y R T -P C R will be perf or me d at least at S cree ni n g a n d a d missi o n visit s. F or partici pa nts a d mitte d f or resi de nce, a s u bse q ue nt 
C O VI D -1 9 test will be perf or me d after 4 da ys (ie, u p o n c o m pleti o n of 4 × 2 4 h o urs i n h o use), or if t he y de vel o p C O VI D- 1 9 li ke s y m pt o m s.
p.
T o be d o ne at least dail y d uri n g resi de nce. 
C CI
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 14
Treatment A (Midazolam): Day 1 through Day 3
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 8
Schedule for Treatment A
Days Relative to Day 1
Day 1
Day 2
Day 3a
Time Relative to Midazolam 
Dosing (hour)
0
0.5
1
2
3
4
6
8
10
12
16
24
36
48
CRU confinement














Safety laboratoryb
X
TSH & Free T4
X
12-lead ECG (triplicate)c
X
X
Vital signs (BP/PR/RR)d
X
X
X
COVID-19 check temperaturee
X
X
X
Midazolam administrationf
X
PK Blood Sampling for 
Midazolamg
Xh
X
X
X
X
X
X
X
X
X
X
X
X
Serious and non-serious AE
monitoring














Concomitant treatment














a.
When Treatment A falls in Period 3, Day 3 corresponds to study Day 27 (day of discharge) and any Day 27 assessments will be required in addition to the Day 3 assessments 
outlined in this table.
b.
Safety laboratory assessments including urinalysis, hematology, chemistry, and coagulation. All the safety laboratory samples must be collected following at least a 4-hour 
fast. Additional safety laboratory assessments may be performed any time at the discretion of the Investigator. 
c.
Triplicate 12-lead ECG readings approximately 2 minutes apart will be taken at specified times. All ECG assessments will be made after at least a 5-minute rest in a supine 
position and prior to any blood draws or vital sign measurements. 
d.
Single supine BP and PR will be performed following at least a 5-minute rest in a supine position. BP, RR, and PR assessments will be performed after collection of ECGs 
and prior to collection of blood draws if planned together. 
e.
To be done at least daily during residence.
f.
Participants will receive a single oral dose of 2 mg midazolam on the morning of Day 1.
g.
One (approximately 3 mL) blood sample for PK analysis of midazolam will be collected. 
h.
Predose midazolam dose.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 1 5
Tre at me nt B ( P F -0 7 3 2 1 3 3 2/rit o n a vir wit h Mi d az ol a m): D a y 1 t hr o u g h D a y 1 2
Visit I de ntifier
A b bre viati o ns use d i n t his ta ble ma y be 
f o u n d i n A p pe n di x 8
Sc he d ule f or Tre at me nt B
D a ys Rel ati ve t o D a y 1
D a y 1
D a y 2
D a y 3
D a y 4
D a y 5
D a y 6
D a y 7
D a y 8
D a y 1 0
D a y 1 2 a
C R U c o nfi ne me nt
 
 
 
 
 
 
 
 


Safet y la b orat or yb
X
X
X
T S H & Free T 4
X
X
X
1 2 -lea d E C G (tri plicate) c
X
X
X
Vital si g ns ( B P/ P R/ R R) d
X
X
X
X
C O VI D -1 9 c hec k te m perat uree
X
X
X
X
X
X
X
X
X
X
Mi daz ola m a d mi nistrati o n f
X
P F -0 7 3 2 1 3 3 2/rit o na vir a d mi nistrati o n g
X
X
X
X
X
P K Bl o o d Sa m pli n g f or mi daz ola m h
X
X
X
X
P K Bl o o d Sa m pli n g f or 
P F -0 7 3 2 1 3 3 2 /rit o na viri
X
X
X  
X  
X  
X

 
 

 




Bl o o d/ Plas ma rati o sa m ple

 
 

X 
 




Seri o us a n d n o n -seri o us A E m o nit ori n g
 
 
 
 
 
 
 
 


C o nc o mita nt treat me nt
 
 
 
 
 
 
 
 


a.
W he n Treat me nt B falls i n Peri o d 3, Da y 1 2 c orres p o n ds t o st u d y Da y 2 7 ( da y of disc har ge) a n d a n y Da y 2 7 assess me nts will be r e q uire d i n a d diti o n t o t he Da y 1 2 
assess me nts o utli ne d i n t his ta ble.
b.
Safet y la b orat or y assess me nts i ncl u di n g uri nal ysis, he mat ol o g y, c he mistr y, a n d c oa g ulati o n. All t he safet y la b orat or y sa m ples m ust be c ollecte d f oll o wi n g at least a 4 -h o ur 
fast. A d diti o nal safet y la b orat or y assess me nts ma y be perf or me d a n y ti me at t he discreti o n of t he I n vesti gat or. 
c.
Tri plicate 1 2 -lea d E C G rea di n gs a p pr o xi matel y 2 mi n utes a part will be ta ke n at s pecifie d ti mes. All E C G assess me nts will be ma de after at least a 5 - mi n ute rest i n a s u pi ne 
p ositi o n a n d pri or t o a n y bl o o d dra ws or vital si g n meas ure me nts. 
d.
Si n gle s u pi ne B P a n d P R will be perf or me d f oll o wi n g at least a 5 - mi n ute rest i n a s u pi ne p ositi o n. B P, R R, a n d P R  assess me nts will be perf or me d after c ollecti o n of E C Gs 
a n d pri or t o c ollecti o n of bl o o d dra ws if pla n ne d t o get her.
e.
T o be d o ne at least dail y d uri n g resi de nce.
f.
Partici pa nts will recei ve a si n gle oral d ose of 2 m g mi daz ola m o n t he m or ni n g of Da y 5, a d mi nistere d wit h P F - 0 7 3 2 1 3 3 2/rit o na vir. 
g.
P F - 0 7 3 2 1 3 3 2/rit o na vir will be a d mi nistere d orall y, q 1 2 h f or a t otal of 9 d oses. P F -0 7 3 2 1 3 3 2 a n d rit o na vir will be d ose d si m ulta ne o usl y ( wit hi n n o m ore t ha n 5 mi n utes of 
eac h ot her).
h.
O ne (a p pr o xi matel y 3 m L) bl o o d sa m ple f or P K a nal ysis of mi daz ola m will be ta ke n acc or di n g t o t he ti mes s pecifie d i n t he Detaile d Sa m pli n g Sc he d ul e bel o w.
i.
O ne (a p pr o xi matel y 3 m L) bl o o d sa m ple f or P K a nal ysis of P F - 0 7 3 2 1 3 3 2 a n d rit o na vir will be ta ke n acc or di n g t o t he ti mes s pecifie d i n t he Detaile d Sa m pli n g Sc he d ule 
bel o w.
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 1 6
Tre at me nt B ( P F -0 7 3 2 1 3 3 2/rit o n a vir wit h Mi d az ol a m): Det aile d S a m pli n g Sc he d ule
Visit I de ntifier
A b bre viati o ns use d i n t his ta ble ma y be 
f o u n d i n A p pe n di x 8
Det aile d Sc he d ule f or Tre at me nt B
Tre at me nt B St u d y D a y
D a y 1
D a ys 2 - 4
D a y 5
D a y 6  
D a y 7  
D a y 8
D a y 1 2 a
Pl a n ne d H o urs P ost M or ni n g D ose
0
1 2
0
1 2
0
0. 5
1 
2 
3 
4 
6 
8
1 0 
1 2 
1 6 
2 4 
3 6 
4 8 
7 2
P F - 0 7 3 2 1 3 3 2/rit o na vir a d mi nistrati o n
X  
X  
X  
X  
X
Mi daz ola m a d mi nistrati o n
X
P K Bl o o d Sa m pli n g f or 
P F -0 7 3 2 1 3 3 2 /rit o na vir
X b
X b
X b
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X
P K Bl o o d Sa m pli n g f or mi daz ola m
X c
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X
Bl o o d/ Plas ma rati o sa m ple e
X b
X
1 2 -lea d E C G (tri plicate)
X b
X b
X b
X
X
Vital si g ns ( B P/ P R/ R R)
X b
X b
X b
X
X
T S H & Free T 4
X b
X
X
Safet y la b orat or y
X b
X
X
a.
W he n Treat me nt B falls i n Peri o d 3, Da y 1 2 c orres p o n ds t o st u d y Da y 2 7 ( da y of disc har ge) a n d a n y Da y 2 7 assess me nts will be r e q uire d i n a d diti o n t o t he Da y 1 2 
assess me nts o utli ne d i n t his ta ble.
b.
Pre d ose P F - 0 7 3 2 1 3 3 2/rit o na vir a d mi nistrati on o n Da ys 1 , 3, a n d/ or 5.
c.
Pre d ose mi daz ola m a d mi nistrati o n. 
e.
W h ole bl o o d sa m ple/ali q u ot ( a p pr o xi matel y1 5 0 μ L) f or i n vi v o bl o o d/ plas ma rati o assess me nt.
C CI
C CI
C CI
C CI
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 17
Treatment C (Ritonavir with Midazolam): Day 1 through Day 12
Visit Identifier
Abbreviations used in this table may be 
found in Appendix 8
Schedule for Treatment C
Days Relative to Day 1
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 10
Day 12a
CRU confinement










Safety laboratoryb
X
X
X
TSH & Free T4
X
X
X
12-lead ECG (triplicate)c
X
X
X
Vital signs (BP/PR/RR)d
X
X
X
COVID-19 check temperaturee
X
X
X
X
X
X
X
X
X
X
Midazolam administrationf
X
Ritonavir administrationg
X
X
X
X
X
PK Blood Sampling for midazolamh
X
X
X
X
Serious and non-serious AE monitoring










Concomitant treatment










a.
When Treatment C falls in Period 3, Day 12 corresponds to study Day 27 (day of discharge) and any Day 27 assessments will be required in addition to the Day 12 
assessments outlined in this table.
b.
Safety laboratory assessments including urinalysis, hematology, chemistry, and coagulation. All the safety laboratory samples must be collected following at least a 4-hour 
fast. Additional safety laboratory assessments may be performed any time at the discretion of the Investigator. 
c.
Triplicate 12-lead ECG readings approximately 2 minutes apart will be taken at specified times. All ECG assessments will be made after at least a 5-minute rest in a supine 
position and prior to any blood draws or vital sign measurements. 
d.
Single supine BP and PR will be performed following at least a 5-minute rest in a supine position. BP, RR, and PR assessments will be performed after collection of ECGs 
and prior to collection of blood draws if planned together. 
e.
To be done at least daily during residence.
f.
Participants will receive a single oral dose of 2 mg midazolam on the morning of Day 5, administered with ritonavir.
g.
Ritonavir will be administered orally, q12h for a total of 9 doses. 
h.
One (approximately 3 mL) blood sample for PK analysis of midazolam will be taken according to the times specified in the Detailed Sampling Schedule below. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 18
Treatment C (Ritonavir with Midazolam): Detailed Sampling Schedule
Visit Identifier 
Abbreviations used in this table may be 
found in Appendix 8
Detailed Schedule for Treatment C
Treatment C Study Day
Day 1
Days 2 -4
Day 5
Day 6
Day 
7
Day 
8
Day 12a
Planned Hours Post Morning Dose 
0
12
0
12
0
0.5
1
2
3
4
6
8
10
12
16
24
36
48
72
Ritonavir administration
X
X
X
X
X
Midazolam administration
X
PK Blood Sampling for midazolam
Xb
X
X
X
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG (triplicate)
Xc
Xc
Xc
X
X
Vital signs (BP/PR/RR)
Xc
Xc
Xc
X
X
TSH & Free T4
Xc
X
X
Safety laboratory
Xc
X
X
a.
When Treatment C falls in Period 3, Day 12 corresponds to study Day 27 (day of discharge) and any Day 27 assessments will be required in addition to the Day 12 
assessments outlined in this table.
b.
Predose midazolam administration 
c.
Predose ritonavir administration on Days 1, 3, and/or 5.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 19
2. INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease that is 
currently being developed as an oral treatment of COVID-19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF-07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious. 
2.1. Study Rationale 
The purpose of the study is to evaluate the effect of PF-07321332/ritonavir and ritonavir on 
the PK of midazolam, a CYP3A4 substrate, in healthy participants. Results from this study 
will provide guidance for dosing recommendations with concomitant medications during 
Phase 3 development and further establish the safety margins of PF-07321332/ritonavir.
2.2. Background 
In December 2019, COVID-19 was identified as a new, potentially fatal, respiratory infection 
caused by the novel coronavirus, SARS-CoV-2. The WHO declared COVID-19 a Public 
Health Emergency of International Concern on 20 January 2020 and further characterized the 
disease outbreak as a pandemic on 11 March 2020.1
PF-07321332 is an orally bioavailable 3CLpro inhibitor shown to be effective against 
SARS-CoV-2 3CLpro (Ki = 0.00311 µM) in a biochemical enzymatic assay. Since the 
3CLpro from human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzyme, the ability of PF-07321332 to inhibit the 3CLpro
of other coronaviruses (SARS-CoV-1 and HCoV-229E, MERS, HCoV-OC43, HCoV-HKU1, 
and HCoV-NL63) was also confirmed, indicating a potential for broad 
spectrum -anti-coronavirus activity. The coronavirus 3CL protease is a virally encoded 
enzyme that is critical to the SARS-CoV-2 replication cycle, analogous to other obligatory 
virally encoded proteases (eg-, HIV Protease, HCV Protease).2 PF-07321332 is being 
developed as an oral treatment in patients with COVID-19 infection. 
Ritonavir is a strong CYP3A4 inhibitor being used to inhibit the metabolism of PF-07321332 
in order to increase plasma concentrations of PF-07321332 to values that are anticipated to 
be efficacious. Ritonavir is not expected to have any pharmacological impact on the 
SARS-CoV-2 virus. Ritonavir is being used only as a PK boosting agent.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology of PF-07321332 can be found in the current IB.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Hepatic CYP3450 enzymes were identified as the main pathway for clearance of 
PF-07321332 in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey, and human), 
hepatocytes (rat, monkey, and human), and in vivo in rat and monkey after repeat oral 
dosing. In a reaction phenotyping study using human liver microsomes in the presence of 
selective CYP inhibitors, CYP3A4 was predicted to be the major contributor (fm = 0.99) to 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 20
the in vitro oxidative metabolism of PF-07321332. No significant CYP3A5 contribution is 
expected to the metabolism of PF-07321332. Urinary excretion of PF-07321332 following 
single IV or oral doses in rats was approximately 17%, suggesting minor urinary 
contributions to the overall elimination of PF-07321332. 
Additional information of the nonclinical PK and metabolism of PF-07321332 is available in 
the current IB.
2.2.3. Nonclinical Safety
There were no adverse findings observed in repeat-dose toxicity studies in rats and monkeys 
up to 2 weeks duration and the NOAELs were the highest dose administered (1000 mg/kg 
and 600 mg/kg in the rat and monkey studies, respectively). PF-07321332
related non-adverse, test article-related clinical findings included sporadic occurrence of 
emesis with slight body weight decreases in monkeys. Monitorable and reversible clinical 
pathology findings included those possibly suggestive of low-grade inflammation (in rats and 
monkeys) or alterations in the coagulation pathways (in rats only) without clinical or 
microscopic correlates. Other non-adverse clinical pathology findings were likely due to the 
emesis and subsequent dehydration in monkeys. In rats administered 1000 mg/kg/day, lower 
mean absolute and relative heart weights (females) and higher absolute and relative liver 
weights (both sexes) were observed relative to controls. The lower heart weights had no 
microscopic correlates and were fully reversed at the end of the 2-week recovery period. 
Higher liver weights correlated with reversible, non-adverse microscopic findings of minimal 
to mild severity in the liver and thyroid gland consistent with adaptive changes related to 
microsomal enzyme induction.
PF-07321332 was not mutagenic or clastogenic in in vitro genetic toxicity studies and was 
negative in the in vivo rat micronucleus assay incorporated into the GLP repeat-dose rat 
toxicity study. 
The nonclinical studies performed adequately support the oral administration of 
PF-07321332 in the clinic for up to 14 days.
Further details of the nonclinical safety program are provided in the current IB.
2.2.4. Clinical Overview
Safety, tolerability and PK of PF-07321332 in healthy adult participants is currently being 
explored in an ongoing Phase 1 FIH Study (C4671001). Study C4671001 is a 5-part study 
consisting of SAD (PART-1), MAD (PART-2), relative bioavailability/food effect 
(PART-3), metabolism and excretion study (PART-4), and ECG (PART-5). PART-1 and -2 
are randomized, double-blind, sponsor-open, and placebo controlled to evaluate safety, 
tolerability, and PK of single and multiple escalating oral doses of PF-07321332, 
respectively. PART-3 is randomized and open-label to evaluate relative bioavailability and 
food effect of an oral tablet formulation. PART-4 is open-label, non-randomized, single 
period to evaluate the metabolism and excretion of PF-07321332. PART-5 is a double-blind, 
sponsor-open, randomized, cross-over design to evaluate safety, tolerability and PK at 


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 2 1
s u prat herape utic e x p os ure .
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 2 2
 
 
 
2. 3. Be nefit/ Ris k Assess me nt
P F -0 7 3 2 1 3 3 2/rit o na vir or mi daz ola m are n ot e x pecte d t o pr o vi de a n y cli nical be nefit t o 
healt h y  partici pa nts i n t his st u d y. T his st u d y is desi g ne d pri maril y t o esti mate t he effect of 
m ulti ple d oses of P F - 0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n t he P K of mi daz ola m t o pr o vi de 
g ui da nce f or d osi n g rec o m me n dati o ns wit h c o nc o mita nt me dicati o ns f or 
P F - 0 7 3 2 1 3 3 2/rit o na vir. 
 
 
 
 
 
M ore detaile d i nf or mati o n a b o ut t he k n o w n a n d e x pecte d be nefits a n d ris ks a n d reas o na bl y 
e x pecte d A Es of P F -0 7 3 2 1 3 3 2 ma y  be f o u n d i n t he I B, w hic h is t he S R S D f or P F- 0 7 3 2 1 3 3 2. 
T he S R S Ds f or rit o na vir a n d mi daz ola m are t he c orres p o n di n g E U S m P C 3 a n d Ger ma n 
S m P C 4, res pecti vely. 
C CI
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 23
2.3.1. Risk Assessment
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Intervention(s): PF-07321332
Emesis
Sporadic emesis was observed at ≥100 mg/kg/day of 
PF-07321332 in the 15-day NHP toxicology study (See IB). 
Based on preliminary data, no emesis was observed in the 
FIH Study C4671001 at single doses of PF-07321332 up to 
1500 mg alone and up to 750 mg administered with ritonavir 
(100 mg at -12 h, 0 h, 12 h), and at repeated daily doses 
administered orally for ten days of up to 500 mg 
PF-07321332 q12h with 100 mg ritonavir q12h.
As this is an investigational agent, there is some 
risk that is mitigated by close observation of AEs, 
etc. If needed, palliative care or antiemetics may 
be provided.
Neuronal and pulmonary effects
Transient effect in rat neuronal and pulmonary endpoints 
were observed in rat toxicology study at the high dose level 
(1000 mg/kg as single dose; See IB). Based on preliminary 
data, no AEs suggestive of neuronal or pulmonary effects 
were observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12 h, 0 h, 12 h), and 
at repeated daily doses administered orally for 10 days of up 
to 500 mg PF-07321332 q12h with 100 mg ritonavir q12h.
Vital signs, including respiratory rate, will be 
monitored for pulmonary effect. There will be 
close observation of AEs for any signs of 
neuronal effect. 
Hemodynamic effects
Low level inflammation (increase in fibrinogen) in 15-day 
NHP toxicology study and changes in platelets, globulin and 
albumin/globulin ratio and coagulation system (increase in 
PT and aPTT) in 14-day rat toxicology study (See IB). No 
relevant laboratory changes in inflammatory markers have 
been observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12 h, 0 h, 12 h), and 
at repeated daily doses administered orally for 10 days of up 
to 500 mg PF-07321332 q12h with 100 mg ritonavir q12h.
Fibrinogen, platelets, PT-INR and aPTT, albumin 
and total proteins will be monitored. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 24
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Thyroid function studies
In 14-day rat toxicology study at high dose of PF-07321332 
(1000 mg/kg/day) thyroid gland changes observed were of 
low severity and without evidence of tissue damage. In the 
FIH Study C4671001, 3 participants had TEAEs of elevated 
TSH levels across treatment groups (PF-07321332 or 
placebo with ritonavir 100 mg q12h) in the MAD part of the 
study. There was no clinical correlation with these TSH 
changes and free T4 remained within reference range at all 
times.
TSH and free T4 will be evaluated to monitor 
thyroid function
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and abdominal 
pain).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti-emetics may be provided. 
Neurological disturbances (eg, 
paresthesia, including oral paresthesia, 
dysgeusia and dizziness).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs. 
Rash (most commonly reported as 
erythematous and maculopapular, 
followed by pruritus).
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs and monitoring through 
targeted physical examinations. If needed, 
palliative care may be provided. 
Fatigue/Asthenia.
Frequently reported adverse reaction in HIV patients at 
600 mg BID.
Lower dose used in this study. There will be close 
observation of AEs and monitoring through 
targeted physical examinations.
Limited case reports of renal toxicity
Although ritonavir therapy is not generally considered 
nephrotoxic, a limited number of cases of acute kidney 
injury secondary to ritonavir have been reported post-
marketing in HIV patients.
Lower dose used in this study. There will be close 
observation of AEs and renal function.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 25
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Study Intervention(s): Midazolam
Cardiac and respiratory effects (eg,
respiratory depression, apnea, respiratory 
arrest and/or cardiac arrest, hypotension, 
changes in the heart rate, vasodilation 
effects, dyspnea, laryngospasm)
Adverse reactions reported following midazolam 
administration and concomitant use of inhibitors of CYP3A4
A small and single dose of 2 mg will be 
administered in the study. Participants will be 
monitored by vital signs, ECGs, AEs collection
and targeted physical examination in an inpatient 
clinical research unit.
Hypersensitivity reactions (eg,
bronchospasm, anaphylactic shock, rash, 
urticaria, pruritus)
Adverse reactions reported following midazolam 
administration.
A small and single dose of 2 mg will be 
administered in the study. Participants will be 
monitored by vital signs, ECGs, AEs collection 
and targeted physical examination in an inpatient 
clinical research unit.
Neurological disturbances (eg, drowsiness 
and prolonged sedation, reduced 
alertness, mental confusion, euphoria, 
hallucinations, fatigue, headache, 
dizziness, ataxia, postoperative sedation, 
and anterograde amnesia)
Adverse reactions reported following midazolam 
administration.
A small and single dose of 2 mg will be 
administered in the study. Participants will be 
monitored by vital signs, ECGs, AEs collection 
and targeted physical examination in an inpatient 
clinical research unit.
Paradoxical reactions (eg, agitation, 
involuntary movements (including 
tonic/clonic spasms and muscle tremors), 
hyperactivity, hostility, anger reactions, 
aggressiveness, paroxysmal excitement, 
and violent actions)
Adverse reactions reported following midazolam 
administration.
A small and single dose of 2 mg will be 
administered in the study. Participants will be 
monitored by vital signs, ECGs, AEs collection 
and targeted physical examination in an inpatient 
clinical research unit.
Gastrointestinal disturbances (eg, Nausea, 
vomiting, hiccups, constipation, dry 
mouth)
Adverse reactions reported following midazolam 
administration.
A small and single dose of 2 mg will be 
administered in the study. Participants will be 
monitored by vital signs, ECGs, AEs collection 
and targeted physical examination in an inpatient 
clinical research unit.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 2 6
2. 3. 2. Be nefit Assess me nt
P F -0 7 3 2 1 3 3 2/rit o na vir a n d mi daz ola m will n ot pr o vi de a n y  cli nical be nefit t o healt h y 
partici pa nts i n t his st u d y . A n y a ntici pate d be nefit t o partici pa nts w o ul d be i n ter ms of 
c o ntri b uti o n t o t he pr ocess of de vel o pi n g a ne w t hera p y i n a n area of u n met me dical nee d.
2. 3. 3. O ver all Be nefit /Ris k C o ncl usi o n
P F -0 7 3 2 1 3 3 2/rit o na vir a n d mi daz ola m are n ot e x pecte d t o pr o vi de a n y  cli nical be nefit t o 
healt h y  partici pa nts i n t his st u d y. Ta ki n g i nt o acc o u nt t he meas ures ta ke n t o mi ni mize ris k t o 
partici pa nts of t his st u d y , t he p ote ntial ris ks i de ntifie d i n ass ociati o n wit h a d mi nistrati o n of 
P F -0 7 3 2 1 3 3 2/rit o na vir a n d mi daz ola m are j ustifie d b y  t he a ntici pate d be nefit, i n ter ms of 
c o ntri b uti o n t o t he pr ocess of de vel o pi n g a ne w t hera p y i n a n area of u n met me dical nee d.
3. O B J E C TI V E S A N D E N D P O I N T S
O bjecti ves
E n d p oi nts
Pri m ar y O bjecti ve: 
Pri m ar y E n d p oi nt: 

T o esti mate t he effect of P F -0 7 3 2 1 3 3 2/rit o na vir 
o n t he P K of mi daz ola m

Mi daz ola m plas ma P K para meters: C ma x a n d 
A U C i nf (if data per mit , ot her wise A U Clast) wit h 
P F -0 7 3 2 1 3 3 2/rit o na vir (test) vers us wit h o ut 
P F -0 7 3 2 1 3 3 2/rit o na vir (refere nce)
Sec o n d ar y O bjecti ve: 
Sec o n d ar y E n d p oi nts: 

T o e val uate t he safet y a n d t olera bilit y of 
P F -0 7 3 2 1 3 3 2/rit o na vir i n healt h y partici pa nts i n 
t he a bse nce a n d prese nce of mi daz ola m

T o esti mate t he effect of rit o na vir o n t he P K of 
mi daz ola m

T o e val uate t he effects of 
P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n 
a d diti o nal P K para meters of mi daz ola m i n 
healt h y partici pa nts

Assess me nt of T E A E s, cli nical la b orat or y 
a b n or malities, vital si g ns, a n d 1 2 -lea d E C Gs

Mi daz ola m plas ma P K para meters: C
ma x a n d 
A U C i nf (if data per mit , ot her wise A U Clast) wit h 
rit o na vir (test) vers us wit h o ut rit o na vir 
(refere nce)

Mi d az ola m plas ma P K para meters: T ma x , t½ , 
A U C last, C L/ F, a n d Vz/ F f or mi daz ola m wit h 
a n d wit h o ut c oa d mi nistrati o n of 
P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir
 
 
 
 
 
 
 
 
 
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 27
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1, open-label, 3-treatment, 6-sequence, 3-period crossover study to evaluate 
the effect of steady-state PF-07321332/ritonavir and ritonavir on the PK of midazolam in 
healthy adult participants. The study will consist of 3 treatments: single oral dose of 2 mg 
midazolam alone (Treatment A), multiple oral doses of 300 mg PF-07321332/100 mg 
ritonavir in combination with a single oral dose of 2 mg midazolam (Treatment B), and 
multiple oral doses of 100 mg ritonavir in combination with a single oral dose of 2 mg 
midazolam (Treatment C). There will be a total of 6 treatment sequences shown in Table 1
with the assigned Treatments A, B or C in each period. 
A total of approximately 12 healthy male and/or female participants will be enrolled into the 
study to ensure at least 10 participants will complete the study. Participants who discontinued 
from the study for non-safety reasons may be replaced at the sponsor’s discretion in 
collaboration with the investigator. 
Each participant will be screened to determine eligibility within 28 days prior to study 
treatment. Medical history and results of physical examination, vital signs, 12-lead ECGs, 
and clinical laboratory evaluations will determine eligibility. Eligible participants will report 
to the CRU on Day -1 and will be required to stay in the CRU for 28 days and 27 nights. 
Each enrolled participant will participate in 3 study periods to receive 3 different treatments: 

Treatment A: Single oral dose of 2 mg midazolam, followed by serial PK sampling 
and 2-day washout (Treatment A period duration: Day 1 to Day 3)

Treatment B: 300 mg PF-07321332/100 mg ritonavir administered orally, q12h for 
9 doses: Day 1 morning to Day 5 morning. On Day 5, participants will receive a 
single oral dose of 2 mg midazolam administered with the Day 5 morning dose of 
PF-07321332/ritonavir, followed by serial PK sampling and a 7-day washout
(Treatment B period duration: Day 1 to Day 12). 

Treatment C: 100 mg ritonavir administered orally, q12h for 9 doses: Day 1 morning 
to Day 5 morning. On Day 5, participants will receive a single oral dose of 2 mg 
midazolam administered with the Day 5 morning dose of ritonavir, followed by serial 
PK sampling and a 7-day washout (Treatment C period duration: Day 1 to Day 12).
Participants will be randomly assigned to 1 of 6 sequences as in Table 1. Serial PK samples 
will be collected at timepoints shown in SoA.
Participants will be discharged on Period 3, following completion of all assessments.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 2 8
T a ble 1.
Tre at me nt Se q ue nces
Peri o d 1
Peri o d 2
Peri o d 3
Se q ue nce 1 ( n = 2)
Treat me nt A
Treat me nt B
Treat me nt C
Se q ue nce 2 ( n = 2 )
Treat me nt C
Treat me nt A
Treat me nt B
Se q ue nce 3 ( n = 2 )
Treat me nt B
Treat me nt C
Treat me nt A
Se q ue nce 4 ( n = 2 )
Treat me nt C
Treat me nt B
Treat me nt A
Se q ue nce 5 ( n = 2 )
Treat me nt B
Treat me nt A
Treat me nt C
Se q ue nce 6 ( n = 2 )
Treat me nt A
Treat me nt C
Treat me nt B
If a partici pa nt has a n y cli nicall y si g nifica nt, st u d y relate d a b n or malities at t he c o ncl usi o n of 
a sc he d ule d i n patie nt p orti o n of t he st u d y , t he Pfizer me dical m o nit or ( or desi g nate d 
re prese ntati ve) s h o ul d be n otifie d a n d t he partici pa nt ma y be as ke d t o re mai n i n t he C R U 
u ntil s uc h a b n or malities are dee me d n ot cli nicall y si g nifica nt, or it is safe f or o ut patie nt 
f oll o w- u p.
A safet y f oll o w -u p call will be ma de t o partici pa nts a p pr o xi matel y  2 8 t o 3 5 da ys fr o m 
a d mi nistrati o n of t he fi nal d ose of st u d y  i nter ve nti o n.
T he t otal pla n ne d d urati o n of partici pati o n, fr o m t he Scree ni n g visit t o t he last F oll o w -u p 
p h o ne call, is a p pr o xi matel y  1 3 wee ks.
4. 2. Scie ntific R ati o n ale f or St u d y Desi g n
T his is a P hase 1, o pe n -la bel st u d y t o esti mate t he effect of stea dy stat e
P F -0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n t he P K of mi daz ola m i n healt h y  a d ult partici pa nts. 
P F -0 7 3 2 1 3 3 2 was e xa mi ne d f or i n vitr o i n hi biti o n of t he maj or C Y P a n d U G T e nz y mes, 
i n d ucti o n of t he maj or C Y P e nz ymes, a n d i n hi biti o n of vari o us effl u x, he patic u p ta ke, a n d 
re nal tra ns p orters. Res ults s u g gest t hat P F -0 7 3 2 1 3 3 2 is li kel y t o re versi bl y a n d 
ti me-de pe n de ntl y i n hi bit C Y P 3 A 4 at t he pr o p ose d t hera pe utic d ose. R it o na vir is a p ote nt 
i n hi bit or of C Y P 3 A. A d diti ve D DI ris k is p ossi ble fr o m P F-0 7 3 2 1 3 3 2/rit o na vir b e y o n d w hat 
is p ose d b y rit o na vir al o ne.
T he p ur p ose of t his st u d y is t o esti mate t he effect of P F - 0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir o n 
t he P K of a C Y P 3 A 4 s u bstrate, mi daz ola m, i n healt h y partici pa nts.
4. 2. 1. C h oice of C o ntr ace pti o n/ B arrier Re q uire me nts
H u ma n re pr o d ucti ve safet y  data are li mite d f or P F-0 7 3 2 1 3 3 2, b ut t here is n o s us pici o n of 
h u ma n terat o ge nicit y base d o n t he i nte n de d p har mac ol o g y of t he c o m p o u n d. T heref ore, t he 
use of a hi g hl y effecti ve met h o d of c o ntrace pti o n is re q uire d (see A p pe n di x 4 ).
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 29
4.3. Justification for Dose
This study is designed to estimate the effect of steady-state levels of PF-07321332/ritonavir 
and ritonavir on the PK of a single dose of midazolam. The dose 300 mg 
PF-07321332/100 mg ritonavir or 100 mg ritonavir, administered q12h for 5 days (a total of 
9 doses) will be used. The dose of 300 mg PF-07321332/100 mg ritonavir for 5 days is the 
intended therapeutic dose and duration to be evaluated in Phase 2/3 studies. This dose is 
lower than the highest dose evaluated in the Phase 1 C4671001 study and is expected to be 
safe and well tolerated. 
Midazolam has been administered at doses of 2 to 15 mg to assess CYP3A4/5 DDIs5 and is 
currently recommended for clinical use as a single oral dose (0.25 to 1.0 mg/kg) or IV 
administration. An oral dose of midazolam 2 mg administered once will be used in this study. 
This dose will provide measurable PK for 24 hours and is expected to be well tolerated even 
if PF-07321332/ritonavir and/or ritonavir result in an increase in midazolam plasma 
exposure.
4.4. End of Study Definition
The end of the study is defined as the date of last scheduled procedure shown in the SoA for 
the last participant in the trial.
A participant is considered to have completed the study if he/she has completed all parts of 
the study, including the last scheduled procedure shown in the SoA.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the 
study is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Participants must be 18 to 60 years of age, inclusive, at the time of signing the ICD.

Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female 
(Section 10.4.2) participants.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 30
Type of Participant and Disease Characteristics:
2. Male and female participants who are overtly healthy as determined by medical 
evaluation including medical history, PE, laboratory tests, vital signs, and standard 
12-lead ECGs.
3. Participants who are willing and able to comply with all scheduled visits, treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.
4. Female participants of childbearing potential must have a negative (urine or serum) 
pregnancy test.
Weight:
5. BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
Informed Consent:
6. Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the ICD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
7. Positive test result for SARS-CoV-2 infection at the time of Screening or Day -1.
8. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, asymptomatic, 
seasonal allergies at the time of dosing).
9. Clinically relevant abnormalities requiring treatment (eg, acute myocardial infarction, 
unstable ischemic conditions, evidence of ventricular dysfunction, serious tachy- or 
brady-arrhythmias) or indicating serious underlying heart disease (eg, prolonged PR 
interval, cardiomyopathy, heart failure greater than NYHA 1, underlying structural 
heart disease, Wolff Parkinson-White syndrome). 
10. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
11. History of acute arrow-angle glaucoma, untreated open-angle glaucoma, sleep apnea, 
severe respiratory insufficiency, myasthenia gravis. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 31
12. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
or HCVAb. Hepatitis B vaccination is allowed.
13. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID-19 pandemic (eg, Contact with positive case, residence, 
or travel to an area with high incidence) that may increase the risk of study 
participation or, in the investigator’s judgment, make the participant inappropriate for 
the study.
Prior/Concomitant Therapy:
14. Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study 
intervention. (Refer to Section 6.8 Concomitant Therapy for additional details).
15. Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.8 Concomitant 
Therapy.
16. Participant who have received a COVID-19 vaccine within 7 days before screening or 
admission, or who are to be vaccinated with a COVID-19 vaccine at any time during 
the study confinement period.
Prior/Concurrent Clinical Study Experience:
17. Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study intervention
used in this study (whichever is longer); Participants who have participated in 
previous clinical trials with PF-07321332 may be eligible to participate in this study
as long as they meet all other criteria.
Diagnostic Assessments:
18. A positive urine drug test.
19. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at 
least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility.
20. Baseline standard 12-lead ECG (triplicate) that demonstrates clinically relevant 
abnormalities that may affect participant safety or interpretation of study results (eg,
baseline QTcF interval >450 msec, complete LBBB, signs of an acute or 
indeterminate-age myocardial infarction, ST-T interval changes suggestive of 
myocardial ischemia, second or -third-degree AV block, or serious bradyarrhythmias 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 32
or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this 
interval should be rate -corrected using the Fridericia method and the resulting QTcF 
should be used for decision making and reporting. Computer -interpreted ECGs 
should be overread by a physician experienced in reading ECGs before excluding a 
participant.
21. Participants with ANY of the following abnormalities in clinical laboratory tests at 
screening, as assessed by the study-specific laboratory and confirmed by a single 
repeat test, if deemed necessary: 

AST or ALT level > 1 × ULN;

Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may have direct bilirubin measured and would be eligible for this study 
provided the direct bilirubin level is ≤ULN.

eGFR < 81 mL/min/1.73m2 (eg <90 mL/min/1.73m2 with 10% variation) based 
on the CKD-EPI equation.
Other Exclusions:
22. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 
1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
23. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or 
more within 60 days prior to dosing.
24. Unwilling or unable to comply with the criteria in the Lifestyle Considerations
section of this protocol.
25. Investigator site staff or Pfizer employees directly involved in the conduct of the 
study, site staff otherwise supervised by the investigator, and their respective family 
members.
26. History of sensitivity reactions to ritonavir or midazolam, or any of the formulation 
components of PF-07321332, ritonavir, or midazolam.
27. Pregnant or breastfeeding women.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 33
5.3. Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions

Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any safety laboratory evaluations and at least 10 hours prior to drug administration 
for: 

Dosing of midazolam in Treatment A

Dosing of PF-07321332/ritonavir and midazolam on Day 5 in Treatment B

Dosing of ritonavir and midazolam on Day 5 in Treatment C 

At least a 2-hour fast is required prior to drug administration for all other doses of 
PF-07321332/ritonavir and ritonavir in Treatments B and C. 

Water is permitted until 1 hour prior to study intervention administration. Water may 
be consumed without restriction beginning 1 hour after dosing for all scheduled 
doses. Noncaffeinated drinks (except grapefruit or grapefruit -related citrus fruit 
juices—see below) may be consumed with meals and the evening snack.

PF-07321332 will be administered first and ritonavir will be administered within 5 
minutes of PF-07321332. For treatments B and C, on Day 5 midazolam will be 
administered last, within 10 minutes of PF-07321332 (Treatment B) or ritonavir 
(Treatment C).

A light breakfast is permitted 2 hours after dosing on non-PK days. On PK days 
(Day 1 of Treatment A, and Day 5 of Treatments B and C), no food will be permitted 
for 4 hours after dosing.

Lunch will be provided approximately 4 hours after morning dosing.

Dinner will be provided approximately 9 to 10 hours after morning dosing.

An evening snack may be permitted.

Participants will refrain from consuming red wine, grapefruit, or grapefruit-related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study intervention until collection of the final PK blood sample.

While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein. The daily caloric intake 
per participant should not exceed approximately 3200 kcal.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 34
5.3.2. Caffeine, Alcohol, and Tobacco

Participants will abstain from caffeine-containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study period.

Participants will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample of each study period. Participants may undergo an alcohol 
breath test or blood alcohol test at the discretion of the investigator.

Participants will abstain from the use of tobacco- or nicotine-containing products for 
24 hours prior to dosing and during confinement in the CRU. 
5.3.3. Activity

Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory tests. Walking at a normal pace will be permitted;

In order to standardize the conditions on PK sampling days, participants will be 
required to refrain from lying down (except when required for BP, pulse rate, and 
ECG measurements), eating, and drinking beverages other than water during the first 
4 hours after dosing;

Participants will be confined to the procedure room for the first 4 hours after dosing 
on Day 1, except to use the bathroom. After this, participants may be ambulatory but 
should not engage in strenuous activities.
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities (SoA), the 
investigator or designee will inform the participant of the need to use highly effective
contraception consistently and correctly and document the conversation and the participant’s 
affirmation in the participant’s chart (participants need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy may have changed since the last visit. In addition, the investigator or designee will 
instruct the participant to call immediately if the selected contraception method is 
discontinued or if pregnancy is known or suspected in the participant or partner.
5.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 35
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened.
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study procedure(s) intended to be administered to a study 
participant according to the study protocol.
For the purposes of this protocol, study intervention refers to PF-07321332, ritonavir and
midazolam.
6.1. Study Intervention(s) Administered
100 mg PF-07321332 tablets will be supplied by the sponsor to the CRU in bulk along with 
individual dosing containers for unit dosing.
Commercially available 100 mg ritonavir tablets and midazolam oral solution (2 mg/mL,
30 mL) will be supplied by the CRU.
6.1.1. Administration
Investigational products will be administered orally and according to the conditions 
described in the SoA and Protocol Section 5.3.1 Meals and Dietary Restrictions.
Treatment A: Following an overnight fast of at least 10 hours, participants will receive a 
single dose of 2 mg midazolam administered orally at approximately 0800 hours (plus or 
minus 2 hours). Investigator site personnel will administer midazolam with ambient 
temperature water to a total volume of approximately 240 mL. 
Treatment B: On Period Day 1, following an overnight fast of at least 2 hours, participants 
will receive PF-07321332 300 mg, administered orally with ritonavir 100 mg at 
approximately 0800 hours (plus or minus 2 hours). PF-07321332 and ritonavir will be dosed 
simultaneously (within no more than 5 minutes of each other). Participants will receive 
PF-07321332 300 mg with 100 mg ritonavir orally in a similar fashion approximately every 
12 hours for a total of 9 doses, with the last dose administered following an overnight fast of 
at least 10 hours on the morning of Day 5. At least a 2 hour fast is required for morning doses 
on Days 1, 2, 3 and 4, and all evening doses. On Days 1 to 4, Investigator site personnel will 
administer PF-07321332 and ritonavir with ambient temperature water to a total volume of 
approximately 240 mL. On Day 5, the PF-07321332/ritonavir dose should be 
co-administered with a single oral dose of midazolam 2 mg at approximately 0800 hours 
(plus or minus 2 hours, but within no more than 10 minutes of each other). Investigator site 
personnel will administer PF-07321332 and ritonavir with ambient temperature water to a 
total volume of approximately 240 mL. An additional 100 mL of water will be administered 
with midazolam to ensure complete removal of midazolam solution from the mouth.
Treatment C: On Period Day 1, following an overnight fast of at least 2 hours, participants 
will receive ritonavir 100 mg at approximately 0800 hours (plus or minus 2 hours). 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 36
Participants will receive 100 mg ritonavir orally approximately every 12 hours for a total of 9 
doses, with the last dose administered following an overnight fast of at least 10 hours on the 
morning of Day 5. At least a 2 hour fast is required for morning doses on Days 1, 2, 3, and 4, 
and all evening doses. On Days 1 to 4, Investigator site personnel will administer ritonavir 
with ambient temperature water to a total volume of approximately 240 mL. On Day 5, 
ritonavir dose should be co-administered with a single oral dose of midazolam 2 mg at 
approximately 0800 hours (plus or minus 2 hours, but within no more than 10 minutes of 
each other). Investigator site personnel will administer ritonavir with ambient temperature 
water to a total volume of approximately 240 mL. An additional 100 mL of water will be 
administered with midazolam to ensure complete removal of midazolam solution from the 
mouth.
Participants will swallow all tablet formulations whole and will not manipulate or chew the 
tablets prior to swallowing. 
For Treatments B and C, participants may receive additional ambient temperature water up to
100 mL, if needed. This will be documented by the site. 
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for BP, pulse rate, and ECG 
measurements), eating, and drinking beverages other than water during the first 4 hours after 
dosing.
6.2. Preparation, Handling, Storage, and Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study interventions received and any 
discrepancies are reported and resolved before use of the study intervention. 
2. Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention. All study 
interventions must be stored in a secure, environmentally controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate the minimum and maximum temperatures since previously documented for 
all site storage locations upon return to business.
3. Any excursions from the study intervention label storage conditions should be 
reported to Pfizer upon discovery along with any actions taken. The site should 
actively pursue options for returning the study intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study intervention must be quarantined and not used until Pfizer provides permission 
to use the study intervention. Specific details regarding the definition of an excursion 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 37
and information the site should report for each excursion will be provided to the site 
in the PCRU local/site procedures.
4. Any storage conditions stated in the SRSD will be superseded by the storage 
conditions stated on the label.
5. Study interventions should be stored in their original containers.
6. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor-approved equivalent. All study interventions will be accounted for 
using a study intervention accountability form/record.
7. Further guidance and information for the final disposition of unused study 
interventions are provided in the PCRU’s local/site procedures. All destruction must 
be adequately documented. If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destroyed in 
compliance with applicable environmental regulations, institutional policy, and any 
special instructions provided by Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day of 
discovery.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study intervention ready for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
participant in accordance with this protocol. Local health authority regulations or investigator 
site guidelines may use alternative terms for these activities.
PF-07321332 100 mg and ritonavir 100 mg tablets will be prepared at the CRU in the 
individual dosing containers by 2 operators, 1 of whom is an appropriately qualified and 
experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse 
practitioner, pharmacy assistant/technician, or pharmacist). The tablets will be provided in 
unit dose containers and labeled in accordance with Pfizer regulations and the clinical site’s 
labeling requirements. 
Midazolam 2 mg/mL oral solution will be prepared and dispensed at the CRU in the 
individual oral syringes by 2 operators, 1 of whom is an appropriately qualified and 
experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse 
practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state and 
institutional guidance. The oral solution will be provided in unit dose oral syringes and 
labeled in accordance with Pfizer regulations and the clinical site’s labeling requirements. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 38
CRU staff should refer to the German SmPC4 on how to prepare midazolam for 
administration to participants.
6.3. Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator will assign participant numbers to the participants as they are screened for 
the study. Pfizer will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen 
assigned to the corresponding randomization number.
6.4. Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by a second qualified member of the study site staff. 
When participants are dosed at the site, they will receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.
The dose of study intervention and study participant identification will be confirmed at the 
time of dosing by a member of the study site staff. Study site personnel will examine each 
participant’s mouth to ensure that the study intervention was ingested.
6.5. Dose Modification
No dose modification is anticipated. 
6.6. Continued Access to Study Intervention After the End of the Study
No intervention will be provided to study participants at the end of their study participation.
6.7. Treatment of Overdose
For this study, any dose of PF-07321332 greater than 600 mg, ritonavir greater than 200 mg, 
or midazolam greater than 2 mg within a 24-hour time period ±1 hour will be considered an 
overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1. Contact the medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs and laboratory abnormalities for at 
least 5 half-lives or 28 calendar days after the overdose of PF-07321332, ritonavir or 
midazolam (whichever is longer).


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 39
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.
4. Overdose is reportable to Pfizer Safety only when associated with an SAE.
5. Obtain a blood sample for PK analysis within 3 days from the date of the last dose of 
study intervention if requested by the medical monitor (determined on a case-by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
6.8. Concomitant Therapy
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study 
intervention. Limited use of nonprescription medications that are not believed to affect 
participant safety or the overall results of the study may be permitted on a case-by-case basis 
following approval by the sponsor. Acetaminophen/paracetamol may be used at doses of 
≤1 g/day.
Hormonal contraceptives that meet the requirements of this study are allowed to be used in 
participants who are WOCBP (see Appendix 4).
All concomitant treatments taken during the study must be recorded with indication, daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study intervention will be 
documented as a prior treatment. Treatments taken after the first dose of study intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-07321332, ritonavir or 
midazolam; standard medical supportive care must be provided to manage the AEs. 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
It may be necessary for a participant to permanently discontinue study intervention. Reasons 
for permanent discontinuation of study intervention include the following:

AE requiring discontinuation in investigator’s view;

Pregnancy;


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 40

Positive COVID-19 test.
If study intervention is permanently discontinued, the participant will not remain in the study 
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
study intervention.
7.1.1. ECG Changes
A participant who meets either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the study intervention. 

QTcF >500 msec.

Change from baseline: QTcF >60 msec and QTcF >450 msec.
If a clinically significant finding is identified (including, but not limited to, changes from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study and if any change in participant management is 
needed. This review of the ECG printed at the time of collection must be documented. Any 
new clinically relevant finding should be reported as an AE.
7.1.2. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney injury, are considered potential 
cases of acute kidney injury and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L) in SCr level relative to the participant’s own 
baseline measurement should trigger a halt/stopping of dosing, followed by another 
assessment of SCr as soon as practically feasible, preferably within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 µmol/L] in SCr
relative to the participant’s own baseline measurement) confirms the observation of 
≥0.3 mg/dL (or ≥26.5 µmol/L), the participant should be discontinued from the study and 
adequate, immediate, supportive measures taken to correct apparent acute kidney injury.
Participants should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the abnormal SCr result. This evaluation 
should include laboratory tests, detailed history, and physical assessment. In addition to 
repeating SCr, laboratory tests should include serum BUN, serum creatine kinase, and serum 
electrolytes (including at a minimum potassium, sodium, phosphate/phosphorus, and 
calcium), in addition to urinary dipstick, urine microscopic examination, and urinary indices. 
All cases confirmed on repeat testing as meeting the laboratory criteria for acute kidney 
injury, with no other cause(s) of laboratory abnormalities identified, should be considered 
potential cases of drug-induced kidney injury irrespective of availability of all the results of 
the investigations performed to determine etiology of the abnormal SCr. If ≥2 healthy 
participants are noted to have 2 consecutive SCr results change from baseline of ≥0.3 mg/dL 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 41
(or ≥26.5 µmol/L), an assessment of whether the finding may be considered an adverse drug 
reaction should be undertaken.
7.1.3. Stopping Rules
Dosing will be halted at any time if 1 of the following circumstances occurs and it is 
determined by the investigator that the occurrence is at least possibly related to the 
administration of study drug:

A SAE (eg, a serious AE considered at least possibly related to study drug 
administration) in 1 participant.

Severe NSAE (eg, severe NSAEs considered at least possibly related to study drug 
administration) in 2 participants, independent of within or not within the same SOC.
When stopping rules are met, a data review will be conducted by the sponsor and 
investigator. If integrated analysis of available data leads to the conclusion that further dosing 
is justified, an amendment to the protocol may be required if additional safety monitoring is 
warranted.
7.2. Participant Discontinuation/Withdrawal From the Study
A participant may withdraw from the study at any time at his/her own request. Reasons for 
discontinuation from the study include the following:

Refused further study procedures;

Lost to follow-up;

Death;

Study terminated by sponsor;

Investigator decision

Pregnancy
At the time of discontinuing from the study, if possible, an early discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed. 
The early discontinuation visit applies only to participants who are enrolled/randomized and 
then are prematurely withdrawn from the study. Participants should be questioned regarding 
their reason for withdrawal.
The participant will be permanently discontinued from the study intervention and the study at 
that time.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 42
If a participant withdraws from the study, he/she may request destruction of any remaining 
samples taken and not tested, and the investigator must document any such requests in the 
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study intervention will remain in the study 
and must continue to be followed for protocol-specified follow-up procedures. The only 
exception to this is when a participant specifically withdraws consent for any further contact 
with him or her or persons previously authorized by the participant to provide this 
information. Participants should notify the investigator in writing of the decision to withdraw 
consent from future follow-up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records by the investigator, as to whether the withdrawal is 
only from further receipt of study intervention or also from study procedures and/or 
posttreatment study follow-up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in 
accordance with local law.
7.3. Lost to Follow-up 
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to attend a required study visit:

The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study;

Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record;

Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 43
8. STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any study-specific procedures.
Study procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety issues should be discussed with the sponsor immediately upon occurrence or 
awareness to determine whether the participant should continue or discontinue study 
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment), then participants do not require rescreening if the laboratory results obtained prior 
to first dose administration meet eligibility criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory results 
obtained prior to the first dose administration meet eligibility criteria for this study. In 
addition, other clinical assessments or specimen collections, eg, banked biospecimens, may 
be used without repeat collection, as appropriate.
Every effort should be made to ensure that protocol-required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that may make it unfeasible to perform 
the test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol-required test cannot be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 44
The total blood sampling volume for individual participants in this study is approximately 
417.7 mL. The actual collection times of blood sampling may change. Additional blood 
samples may be taken for safety assessments at times specified by Pfizer, provided the total 
volume taken during the study does not exceed 550 mL during any period of 56 consecutive 
days.
To prepare for study participation, participants will be instructed on the information in the 
Lifestyle Considerations and Concomitant Therapy sections of the protocol.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety issues.
8.2.1. Physical Examinations
A complete physical examination will include, at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and 
neurological systems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory and cardiovascular systems, and participant-reported symptoms.
Physical examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only 
light clothing remains. They must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study will be considered source data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE (Appendix 3) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.
8.2.2. Vital Signs
Supine BP will be measured with the participant’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 45
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements. 
The same properly sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least 
30 seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.
8.2.2.1. Respiratory Rate 
Respiratory rate will be measured after approximately 5 minutes of rest in a supine position 
by observing and counting the respirations of the participant for 30 seconds and multiplying
by 2. When BP is to be taken at the same time, respiration measurement will be done during 
the 5 minutes of rest and before BP measurement.
8.2.2.2. Temperature 
Temperature will be measured orally. No eating, drinking, or smoking is allowed for 
15 minutes prior to the measurement.
8.2.3. Electrocardiograms
Standard 12-lead ECGs utilizing limb leads (with a 10 second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason-Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietly for at least 5 minutes in a supine position. 
Triplicate 12-lead ECGs will be obtained approximately 2 to 4 minutes apart; the average of 
the triplicate ECG measurements collected before dose administration on Day 1 of each 
period will serve as each participant’s baseline QTc value. 
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTcF interval is increased by ≥60 msec from the baseline and is >450 msec; or b) 
an absolute QT value is ≥500 msec for any scheduled ECG. If either of these conditions 
occurs, then 2 additional ECGs will be collected approximately 2 to 4 minutes apart to 
confirm the original measurement. If the QTc values from these repeated ECGs remain above 
the threshold value, then a single ECG must be repeated at least hourly until QTc values from 
2 successive ECGs fall below the threshold value that triggered the repeat measurement.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 46
To ensure safety of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) the mean 
value from the triplicate measurements for any postdose QTcF interval is increased by 
≥60 msec from the baseline and is >450 msec; or b) an absolute QT value is ≥500 msec for 
any scheduled ECG. If either of these conditions occurs, then a single ECG measurement 
must be repeated at least hourly until QTc values from 2 successive ECGs fall below the 
threshold value that triggered the repeat measurement.
If a) a postdose QTcF interval remains ≥60 msec from the baseline and is >450 msec; or b) 
an absolute QT value is ≥500 msec for any scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator); or c) QTcF intervals get progressively longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTcF intervals do not return to less than the criteria listed above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safety laboratory tests to be performed and the SoA for 
the timing and frequency. All protocol required laboratory assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory measurements may be obtained at any time during the study 
to assess any perceived safety issues.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF. 
Clinically significant abnormal laboratory findings are those which are not associated with 
the underlying disease, unless judged by the investigator to be more severe than expected for 
the participant's condition.
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 48 hours after the last dose of study intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by 
the investigator, the etiology should be identified and the sponsor notified.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 47
See Appendix 6 for suggested actions and follow-up assessments in the event of potential 
drug-induced liver injury.
8.2.5. COVID-19 specific assessments 
Participants will be tested for SARS-COVID-19 infection by RT-PCR prior to being 
admitted to the clinic for confinement and a subsequent COVID-19 test will be performed 
after 4 days (ie, upon completion of 4 x 24 hours in house), or if they develop COVID-19 
like symptoms. Additional testing may be required by local regulations or by the Principal 
Investigator.
8.2.6. Pregnancy Testing 
Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least 
25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA.
Following a negative pregnancy test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the study intervention. Pregnancy tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be 
repeated if requested by IRBs/ ECs or if required by local regulations. If a urine test cannot 
be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In 
such cases, the participant must be excluded if the serum pregnancy result is positive.
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may arise from symptoms or other complaints reported to the investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, or the participant's legally 
authorized representative), or they may arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, each participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 48
which is obtained before the participant’s participation in the study (ie, before undergoing 
any study-related procedure and/or receiving study intervention), through and including a 
minimum of 28 calendar days, except as indicated below, after the last administration of the 
study intervention.
Follow-up by the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporarily discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant has concluded study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has completed the study, and he/she 
considers the event to be reasonably related to the study intervention, the investigator must 
promptly report the SAE to Pfizer using the CT SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety on the CT SAE Report Form immediately upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1, will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed and all spontaneously reported 
AEs and SAEs reported by the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as described in Section 5.4.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 49
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.
8.3.3. Follow-Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow-up (as defined in Section 7.3).
In general, follow-up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety. 
Further information on follow-up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of a 
study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country-specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for SUSARs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study intervention. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 50
exposure include healthcare providers, family members, and others who may be exposed. An 
environmental exposure may include exposure during pregnancy, exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study intervention under study are reportable to Pfizer Safety 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if:

A female participant is found to be pregnant while receiving or after discontinuing 
study intervention.

A male participant who is receiving or has discontinued study intervention exposes a 
female partner prior to or around the time of conception.

A female is found to be pregnant while being exposed or having been exposed to 
study intervention due to environmental exposure. Below are examples of 
environmental EDP: 

A female family member or healthcare provider reports that she is pregnant after 
having been exposed to the study intervention by ingestion.

A male family member or healthcare provider who has been exposed to the study 
intervention by ingestion then exposes his female partner prior to or around the 
time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy). 

If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy will be collected after the start of study intervention and until 28 days after 
the last dose.

If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed CT SAE Report Form is maintained in the investigator site file.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 51
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live-born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy outcomes that are reported to 
Pfizer Safety as SAEs follows: 

Spontaneous abortion including miscarriage and missed abortion;

Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention. 
Additional information regarding the EDP may be requested by the sponsor. Further 
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:

A female participant is found to be breastfeeding while receiving or after 
discontinuing study intervention.

A female is found to be breastfeeding while being exposed or having been exposed to 
study intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study intervention 
by ingestion.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 52
The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study, so the information is not recorded on a 
CRF. However, a copy of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specifically 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any instance of occupational exposure to Pfizer Safety within 24 
hours of the investigator’s awareness using the CT SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
AESIs are examined as part of routine safety data review procedures throughout the clinical 
trial and as part of signal detection processes.
All AESIs must be reported as an AE or SAE following the procedures described in 
Section 8.3.1 through 8.3.4. An AESI is to be recorded as an AE or SAE on the CRF. In 
addition, an AESI that is also an SAE must be reported using the CT SAE Report Form.
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy is not expected in the study population.
8.3.9. Medical Device Deficiencies
Not applicable. 


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5 3
8. 3. 1 0. Me dic ati o n Err ors
Me dicati o n err ors ma y  res ult fr o m t he a d mi nistrati o n or co ns u m pti o n of t he st u d y 
i nter ve nti o n b y  t he wr o n g partici pa nt , or at t he wr o n g ti me, or at t he wr o n g d osa ge stre n gt h.
E x p os ures t o t he st u d y i nter ve nti o n u n der st u d y m a y occ ur i n cli nical trial setti n gs, s uc h as 
me dicati o n err ors.
S afet y E ve nt
Rec or de d o n t he C R F
Re p orte d o n t he C T S A E Re p ort 
F or m t o Pfizer S afet y Wit hi n 
2 4 H o urs of A w are ness
Me dicati o n err ors 
All (re gar dless of w het her 
ass ociate d wit h a n A E)
O nl y  if ass ociate d wit h a n S A E
Me dicati o n err ors i ncl u de:

Me dicati o n err ors i n v ol vi n g partici pa nt e x p os ure t o t he st u d y i nter ve nti o n;

P ote ntial me dicati o n err ors or uses o utsi de of w hat is f oresee n i n t he pr ot oc ol t hat d o 
or d o n ot i n v ol ve t he st u d y partici pa nt .
S uc h me dicati o n err ors occ urri n g t o a st u d y partici pa nt are t o be ca pt ure d o n t he me dicati o n 
err or pa ge of t he C R F, w hic h is a s pecific versi o n of t he A E pa ge.
I n t he e ve nt of a me dicati o n d osi n g err or, t he s p o ns or s h o ul d be n otifie d wit hi n 2 4 h o urs .
W het her or n ot t he me dicati o n err or is acc o m pa nie d b y  a n A E, as deter mi ne d b y t he 
i nvesti gat or, t he me dicati o n err or is rec or de d o n t he me dicati o n err or pa ge of t he C R F a n d, if 
a p plica ble, a n y ass ociate d A E(s), seri o us a n d n o nseri o us, are rec or de d o n t he A E pa ge of t he 
C R F.
Me dicati o n err ors s h o ul d be re p orte d t o Pfizer Safet y wit hi n 2 4
h o urs o n a C T S A E Re p ort 
F or m o nl y w he n ass oci ate d wit h a n S A E.
8. 4. P h ar m ac o ki netics 
Bl o o d sa m ples of a p pr o xi matel y  3 m L , t o pr o vi de ap pr o xi matel y 1. 5 m L plas ma , will be 
c ollecte d f or meas ure me nt of plas ma c o nce ntrati o ns of mi daz ola m as s pecifie d i n t he S o A . 
A d diti o nall y , bl o o d sa m ples of a p pr o xi matel y 3 m L , t o pr o vi de ap pr o xi matel y  1. 5 m L  
plas ma, will be c ollecte d f or meas ure me nt of plas ma c o nce ntrati o ns of P F -0 7 3 2 1 3 3 2 a n d 
rit o na vir as s pecifie d i n t he S o A .
I nstr ucti o ns f or t he c ollecti o n a n d ha n dli n g of bi ol o gical sa m ples will be pr o vi de d i n t he 
C CI
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5 4
la borat or y ma n ual or b y  t he s p o ns or. T he act ual date a n d ti me ( 2 4-h o ur cl oc k ti me) of eac h 
sa m ple will be rec or de d.
T he act ual ti mes ma y  c ha n ge, b ut t he n u m ber of sa m ples will re mai n t he sa me. All eff orts 
will be ma de t o o btai n t he sa m ples at t he e xact n o mi nal ti me relati ve t o d osi n g. C ollecti o n of 
sa m ples u p t o a n d i ncl u di n g 1 0 h o urs after d ose a d mi nistrati o n t hat are o btai ne d wit hi n 
1 0 % of t he n o mi nal ti me relati ve t o d osi n g (e g, wit hi n 6 mi n utes of a 6 0 -mi n ute sa m ple) will 
n ot be ca pt ure d as a pr ot oc ol de viati o n, as l o n g as t he e xact ti me of t he c ollecti o n is n ote d o n 
t he s o urce d oc u me nt a n d t he C R F. C ollecti o n of sa m ples m ore t ha n 1 0 h o urs after d ose
a d mi nistrati o n t hat are o btai ne d ≤1 h o ur a wa y  fr o m t he n o mi nal ti me relati ve t o d osi n g will 
n ot be ca pt ure d as a pr ot oc ol de viati o n, as l o n g as t he e xact ti me of t he c ollecti o n is n ote d o n 
t he s ource d oc u me nt a n d t he C R F. T his pr ot oc ol de viati o n wi n d o w d oes n ot a p pl y  t o sa m ples 
t o be c ollecte d m ore t ha n 1 0 h o urs after d ose a d mi nistrati o n at o ut patie nt/f oll o w -u p visits 
wit h visit wi n d o ws.
Sa m ples will be use d t o e val uate t he P K of mi daz ola m, P F -0 7 3 2 1 3 3 2 a n d rit o na vir . Sa m ples 
ma y  als o be use d t o e val uate safet y or efficac y as pects relate d t o c o ncer ns arisi n g d uri n g or 
after t he st u d y, f or meta b olite i de ntificati o n a n d/ or e val uati o n of t he bi oa nal ytical met h o d,
Ge netic a nal ys es will n ot be perf or me d o n t hese plas ma sa m ples u nless c o nse nt f or t his was 
i ncl u de d i n t he i nf or me d c o nse nt. Partici pa nt c o nfi de ntialit y will be mai ntai ne d.
Sa m ples c ollecte d f or meas ure me nt of plas ma c o nce ntrati o ns of mi daz ola m, P F -0 7 3 2 1 3 3 2 
a n d rit o na vir will be a nal y ze d usi n g a vali date d a nal ytical met h o d i n c o m plia nce wit h 
a p plica ble S O Ps.
T he P K sa m ples m ust be pr ocesse d a n d s hi p pe d as i n dicate d i n t he i nstr ucti o ns pr o vi de d t o 
t he i n vesti gat or site t o mai ntai n sa m ple i nte grit y. A n y  de viati o ns fr o m t he P K sa m ple 
ha n dli n g pr oce d ure (e g, sa m ple c ollecti o n a n d pr ocessi n g ste ps, i nteri m st ora ge or s hi p pi n g 
c o n diti o ns), i ncl u di n g a n y acti o ns ta ke n, m ust be d oc u me nte d a n d re p orte d t o t he s p o ns or.
O n a case -b y -case basis, t he s p o ns or ma y  ma ke a deter mi nati o n as t o w het her sa m ple 
i nte grity has bee n c o m pr o mise d.
A n y  c ha n ges i n t he ti mi n g or a d diti o n of ti me p oi nts f or a n y pla n ne d st u dy assess me nts m ust 
be d oc u me nte d a n d a p pr o ve d b y  t he rele va nt st u d y tea m me m ber a n d t he n arc hi ve d i n t he 
s p o ns or a n d site st u d y files, b ut will n ot c o nstit ute a pr ot oc ol a me n d me nt. T he IR B/ E C will 
be i nf or me d of a n y safet y iss ues t hat re q uire alterati o n of t he safet y m o nit ori n g sc he me or 
a me n d me nt of t he I C D.
C CI
C CI
C CI
C CI
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5 5
 
 
 
 
8. 6. Bi o m ar kers
Bi o mar kers are n ot e val uate d i n t his st u d y .
8. 6. 1. S pecifie d Ge ne E x pressi o n ( R N A) Rese arc h
S pecifie d ge ne e x pressi o n ( R N A) researc h is n ot i ncl u de d i n t his st u d y .
8. 6. 2. S pecifie d Pr otei n Rese arc h 
S pecifie d pr otei n researc h is n ot i ncl u de d i n t his st u d y .
8. 6. 3. S p ecifie d Met a b ol o mic Rese arc h 
S pecifie d meta b ol o mic researc h is n ot i ncl u de d i n t his st u d y .
 
 
 
 
8. 7. I m m u n o ge nicit y Assess me nts
I m m u n o ge nicity assess me nts are n ot i ncl u de d i n t his st u d y .
C CI
C CI
C CI
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 56
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in an SAP, which will be maintained by the sponsor. The 
SAP may modify what is outlined in the protocol where appropriate; however, any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.
9.1. Statistical Hypotheses
There are no statistical hypotheses for this study. 
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
Set
Description
PK Concentration 
Analysis Set
The PK concentration population is defined as all participants 
randomized and treated who have at least 1 concentration in at 
least 1 treatment period.
PK Parameter Analysis 
Set
The PK parameter analysis population is defined as all 
participants randomized and treated who have at least 1 of the 
PK parameters of primary interest in at least 1 treatment 
period.
Should vomiting occur after co-administration of midazolam 
with PF-07321332/ritonavir, the resulting PK parameters from 
that participant from the corresponding period may be 
excluded.
Safety Analysis Set
All participants randomly assigned to study intervention and 
who take at least 1 dose of study intervention. Participants will 
be analyzed according to the product they actually received.
9.3. Statistical Analyses
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 57
9.3.1. Pharmacokinetic Analyses
The interactive effect on PK parameters will be determined by constructing 90% confidence 
intervals around the estimated difference between the Test and Reference treatments using a 
mixed effects model based on natural log transformed data. The mixed effects model will be 
implemented using SAS Proc Mixed, with REML estimation method and Kenward-Roger 
degrees of freedom algorithm.
9.3.1.1. Derivation of Pharmacokinetic Parameters
Plasma PK parameters of midazolam following single dose administration with and without
PF-07321332/ritonavir or ritonavir will be derived (as data permit) from the 
concentration-time data using standard noncompartmental methods as outlined in the Table 
below. Actual PK sampling times will be used in the derivation of PK parameters. In the case 
that actual PK sampling times are not available, nominal PK sampling time will be used in 
the derivation of PK parameters. 
Parameter
Definition
Method of Determination
AUCinfa
Area under the concentration-time curve from time 
zero extrapolated to infinity
AUClast + (Clast*/kel),
where Clast* is the predicted plasma 
concentration at the last quantifiable 
time point from the log-linear 
regression analysis
AUClast
Area under the concentration-time curve from time 
zero to the time of the last quantifiable 
concentration (Clast)
Linear/Log trapezoidal method
Cmax
Maximum plasma concentration during the dosing 
interval
Observed directly from data
Tmax
Time for Cmax
Observed directly from data as time 
of first occurrence
t½
Terminal half-life
Loge(2)/kel, where kel is the terminal 
phase rate constant calculated by a 
linear regression of the log-linear 
concentration-time curve. Only those 
data points judged to describe the 
terminal log-linear decline are used 
in the regression
CL/F
Apparent clearance
Dose/AUCinf
Vz/F
Apparent volume of distribution
Dose/(AUCinf • kel)
a.
If data permit.
Natural log transformed AUCinf (if data permit), AUClast and Cmax will be analyzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect. Estimates of the adjusted mean differences 
(Test-Reference) and corresponding 90% confidence intervals will be obtained from the 
model. The adjusted mean differences and 90% confidence intervals for the differences will 
be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and 90% confidence intervals for the ratios. Midazolam alone is the 


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5 8
Refere nce treat me nt w hilst mi d az ola m + P F -0 7 3 2 1 3 3 2/rit o na vir a n d mi daz ola m + rit o na vir 
are t he Test treat me nts.
9. 3. 2. Pri m ar y E n d p oi nt(s)

Mi daz ola m plas ma P K para meters: C
ma x a n d A U C i nf (if data per mit, ot her wise 
A U C last) wit h P F -0 7 3 2 1 3 3 2/rit o na vir (test) vers us wit h o ut P F - 0 7 3 2 1 3 3 2/rit o na vir 
(refere nce).
9. 3. 3. Sec o n d ar y E n d p oi nt(s)

Mi daz ola m plas ma P K para meters: C
ma x a n d A U C i nf (if data per mit, ot her wise 
A U C last) wit h rit o na vir (test) vers us wit h o ut rit o na vir (refere nce).

Mi daz ola m p las ma P K para meters: Tma x , t½ , A U Clast, C L/ F, a n d Vz/ F f or mi daz ola m 
wit h a n d wit h o ut c oa d mi nistrati o n of P F- 0 7 3 2 1 3 3 2/rit o na vir a n d rit o na vir.
 
9. 3. 5. Ot her S afet y A n al yses
All safet y a nal ys es will be perf or me d o n t he s afet y p o p ulati o n.
A Es, E C Gs, B P, p ulse rate , a n d safet y la b orat or y data will be re vie we d a n d s u m marize d o n 
a n o n g oi n g basis d uri n g t he st u d y  t o e val uate t he safety of partici pa nt s. A ny cli nical 
la b orat or y, E C G, B P, a n d p ulse rate a b n or malities of p ote ntial cli nical c o ncer n will be 
descri be d. Safet y data will be prese nte d i n ta b ular a n d/ or gra p hical f or mat a n d s u m marize d 
descri pti vel y, w here a p pr o priate.
Me dical hist or y  a n d p h ysical e xa mi nati o n a n d ne ur ol o gical e xa mi nati o n i nf or mati o n, as 
a p plica ble, c ollecte d d uri n g t he c o urse of t he st u d y will be c o nsi dere d s o urce data a n d will 
n ot be re q uire d t o be re p orte d, u nless ot her wise n ote d. H o we ver, a n y u nt o war d fi n di n gs 
i de ntifie d o n p h ysical a n d/ or ne ur ol o gical e xa mi nati o ns c o n d ucte d d uri n g t he acti ve 
c ollecti o n peri o d will be ca pt ure d as A Es, if t h ose fi n di n gs meet t he defi niti o n of a n A E.
Data c ollecte d at scree ni n g t hat are use d f or i ncl usi o n/e xcl usi o n criteria, s uc h as la b orat or y  
dat a, E C Gs, a n d vital si g ns, will be c o nsi dere d s o urce data, a n d will n ot be re q uire d t o be 
re p orte d, u nless ot her wise n ote d. De m o gra p hic data c ollecte d at scree ni n g will be re p orte d.
 
C CI
C CI
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 5 9
 
9. 5. S a m ple Size Deter mi n ati o n
A sa m ple size of 1 2 parti ci pa nts ( a p pr o xi matel y 2 per se q ue nce) will pr o vi de 9 0 % 
c o nfi de nce i nter vals f or t he differe nce bet wee n treat me nts of ± 0. 1 6 5 0 o n t he nat ural l o g scale 
f or A U Ci nf ( mi daz ola m) wit h 8 0 % c o vera ge pr o ba bilit y. T he f oll o wi n g ta ble prese nts t he 
wi dt h of 9 0 % c o nfi de nce i nter val f or differe nt esti mate d effects:
P ar a meter
Esti m ate d Effect
( 1 0 0 * Test/ Refere nce)
9 0 % CI
CI Wi dt h
A U C i nf
8 0 %
6 7. 8 3 %, 9 4. 3 5 %
2 6. 5 2 %
9 0 %
7 6. 3 2 %, 1 0 6. 1 4 %
2 9. 8 3 %
1 0 0 %
8 4. 7 9 %, 1 1 7. 9 4 %
3 3. 1 4 %
1 5 0 %
1 2 7. 1 9 %, 1 7 6. 9 0 %
4 9. 7 2 %
2 0 0 %
1 6 9. 5 8 %, 2 3 5. 8 7 %
6 6. 2 9 %
2 5 0 %
2 1 1. 9 8 %, 2 9 4. 8 4 %
8 2. 8 6 %
3 0 0 %
2 5 4. 3 8 %, 3 5 3. 8 1 %
9 9. 4 3 %
4 0 0 %
3 3 9. 1 7 %, 4 7 1. 7 4 %
1 3 2. 5 8 %
T hese calc ulati o ns are base d o n esti mates of wit hi n ‑ partici pa nt c oefficie nt of variati o n of 
1 9. 4 1 % f or l o ge A U C i nf ( mi daz ola m), as o btai ne d fr o m t he Pfizer Cli nical P har mac ol o g y 
G ui da nce .
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 60
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study will be conducted in accordance with the protocol and with the following:

Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;

Applicable ICH GCP guidelines;

Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents 
(eg, advertisements) must be reviewed and approved by the sponsor, submitted to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.
Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study participants.
The investigator will be responsible for the following:

Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;

Notifying the IRB/EC of SAEs or other significant safety findings as required by 
IRB/EC procedures;

Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the IRB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 61
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study participants against any immediate hazard, and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participant and answer all questions regarding the study. The 
participant should be given sufficient time and opportunity to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.
The investigator must ensure that each study participant is fully informed about the nature 
and objectives of the study, the sharing of data related to the study, and possible risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her personal study-related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.
The investigator further must ensure that each study participant is fully informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study.
A copy of the ICD(s) must be provided to the participant.
A participant who is rescreened is not required to sign another ICD if the rescreening occurs 
within 10 days from the previous ICD signature date.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 62
10.1.3. Data Protection
All parties will comply with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper 
form and will be password-protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant-specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant-specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study agreement and applicable privacy laws.
10.1.4. Committees Structure
10.1.4.1. Data Monitoring Committee 
This study will not use a DMC.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study or the country in 
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product, 
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by US law.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 63
EudraCT
Pfizer posts clinical trial results on EudraCT for Pfizer-sponsored interventional studies in 
accordance with the format and timelines set forth by EU requirements.
www.pfizer.com
Pfizer posts public disclosure synopses (CSR synopses in which any data that could be used 
to identify individual participants have been removed) on www.pfizer.com for 
Pfizer-sponsored interventional studies at the same time the corresponding study results are
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy 0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy, includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy, includes the publishing of individual participant data. Policy 0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01 January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July 2015.
Data sharing
Pfizer provides researchers secure access to patient-level data or full CSRs for the purposes 
of “bona-fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24 months after study completion. Patient-level data will be anonymized in accordance with 
applicable privacy laws and regulations. CSRs will have personally identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 64
The investigator must ensure that the CRFs are securely stored at the study site in encrypted 
electronic and/or paper form and are password-protected or secured in a locked room to 
prevent access by unauthorized third parties.
The investigator must permit study-related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification may also occur after study completion. It is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy, including definition of study critical data items and 
processes (eg, risk-based initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on-site monitoring), are provided in the IQMP maintained and utilized by 
the sponsor or designee.
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securely for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly and irrevocably deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant's medical records. The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 65
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator, which is maintained by the sponsor.
Description of the use of the computerized system is documented in the Source Document 
Locator, which is maintained by the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.
10.1.8. Study and Site Start and Closure
The study start date is the date on which the clinical study will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study 
start date.
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor if 
requested to do so by the responsible IRB/EC or if such termination is required to protect the 
health of study participants.
Reasons for the early closure of a study site by the sponsor may include but are not limited 
to:

Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines;

Inadequate recruitment of participants by the investigator;

Discontinuation of further study intervention development.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 66
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow-up.
Study termination is also provided for in the clinical study agreement. If there is any conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study may be published or presented at scientific meetings by the 
investigator after publication of the overall study results or 1 year after the end of the study 
(or study termination), whichever comes first. 
The investigator agrees to refer to the primary publication in any subsequent publications,
such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor 
30 days before submission. This allows the sponsor to protect proprietary information and to 
provide comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study- or Pfizer-intervention 
related information necessary for the appropriate scientific presentation or understanding of 
the study results.
For all publications relating to the study, the investigator will comply with recognized ethical 
standards concerning publications and authorship, including those established by the 
International Committee of Medical Journal Editors.
The sponsor will comply with the requirements for publication of the overall study results 
covering all investigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only in their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated by mutual 
agreement.
Authorship of publications for the overall study results will be determined by mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study agreement, the publication policy set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study contact list located in CTMS.
To facilitate access to appropriately qualified medical personnel for study-related medical 
questions or problems, participants are provided with an ECC at the time of informed 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 67
consent. The ECC contains, at a minimum, (a) protocol and study intervention identifiers, (b) 
participant’s study identification number, (c) site emergency phone number active 24 
hours/day, 7 days per week, and (d) Pfizer Call Center number.
The ECC is intended to augment, not replace, the established communication pathways 
between the investigator, site staff, and study team. The ECC is to be used by healthcare 
professionals not involved in the research study only, as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Center number should only be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use by the participant directly; if a participant calls that number directly, he 
or she will be directed back to the investigator site.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 6 8
1 0. 2. A p pe n di x 2: Cli n ic al L a b or at or y Tests
T he f oll o wi n g safet y la b orat or y  tests will be perf or me d at ti mes defi ne d i n t he S o A secti o n of 
t his pr ot oc ol (Ta ble 2) . A d diti o nal la b orat or y res ults ma y be re p orte d o n t hese sa m ples as a 
res ult of t he met h o d of a nal ysis or t he ty pe of a nal y zer use d b y t he cli nical la b orat or y, or as 
deri ve d fr o m calc ulate d val ues. T hese a d diti o nal tests w o ul d n ot re q uire a d diti o nal c ollecti o n 
of bl o o d. U nsc he d ule d cli nical la b orat or y  meas ure me nts ma y be o btai ne d at a n y ti me d uri n g 
t he st u d y t o assess a n y percei ve d safet y iss ues.
T a ble 2.
Pr ot oc ol -Re q uire d S afet y L a b or at or y Assess me nts
H e m at ol o g y
C he mistr y
Uri n al ysis
Ot her
H e m o gl o bi n
H e m at ocrit
R B C c o u nt
M C V
M C H
M C H C
Platelet c o u nt
W B C c o u nt
T otal ne utr o p hils 
( A bs)
E osi n o p hils ( A bs)
M o n oc ytes ( A bs)
Bas o p hils ( A bs)
L y m p h oc ytes ( A bs)
B U N a n d creati ni ne
Gl uc ose (fasti n g)
Calci u m
S o di u m
P otassi u m
C hl ori de
T otal C O 2 ( bicar b o nate)
A S T, A L T
T otal bilir u bi n
Al kali ne p h os p hatase
Uric aci d
Al b u mi n
T otal pr otei n
L ocal Di pstic k:
p H
Gl uc ose ( q ual)
Pr otei n ( q ual)
Bl o o d ( q ual)
Ket o nes
Nitrites
Le u k oc yte esterase
La b orat or y:
Micr osc o p y
a n d 
C ult ure a

S A R S -C o V -2 R T -P C R

Uri ne dr u g scree ni n g c

Pre g na nc y test ( -h C G) d

e G F R [ C K D -E PI]

a P T T

P T -I N R

Fi bri n o ge n

T S H

Free T 4
At scree ni n g o nl y:

F S H b

H Bs A g

H Bs A b

H Bc A b

H C V A b

HI V
a.
O nl y if uri ne di pstic k is p ositi ve f or bl o o d, pr otei n, nitrites , or le u k oc yte esterase a n d c ult ure o nl y if 
bacteri uria .
b.
F or c o nfir mati o n of p ost me n o pa u sal stat us o nl y.
c.
T he mi ni m u m re q uire me nt f or dr u g scree ni n g i ncl u des c ocai ne, T H C, o piates/ o pi oi ds, 
be nz o diaze pi nes, a n d a m p heta mi nes ( ot hers are site a n d st u d y s pecific).
d.
L ocal uri ne testi n g will be sta n dar d f or t he pr ot oc ol u nless ser u m testi n g is re q uire d b y l ocal re g ulati o n 
or I R B/ E C. Ser u m or uri ne -h C G f or fe male partici pa nts of c hil d beari n g p ote ntial.
T he i n vesti gat or m ust re vie w t he la b orat or y re p ort, d oc u me nt t his re vie w, a n d rec or d a n y 
cli nicall y rele va nt c ha n ges occ urri n g d uri n g t he st u d y i n t he A E secti o n of t he C R F.
A n y  re mai ni n g ser u m/ plas ma fr o m sa m ples c ollecte d f or cli nical safety la b orat or y 
meas ure me nts at baseli ne a n d at all ti mes after d ose a d mi nistrati o n ma y  be retai ne d a n d 
st ore d f or t he d urati o n of t he st u d y.C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 69
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting
10.3.1. Definition of AE
AE Definition

An AE is any untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study intervention.

Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.
Events Meeting the AE Definition

Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory test results that meet any of the conditions below must be 
recorded as an AE:

Is associated with accompanying symptoms;

Requires additional diagnostic testing or medical/surgical intervention;

Leads to a change in study dosing (outside of any protocol-specified dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.

Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency and/or intensity of the condition.

New condition detected or diagnosed after study intervention administration,
even though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 70
Events NOT Meeting the AE Definition

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.

Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypothetically might have caused death if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary, the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 71
d. Results in persistent or significant disability/incapacity

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non-pathogenic, is considered serious.
The event may be suspected from clinical symptoms or laboratory findings 
indicating an infection in a participant exposed to a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered synonymous. These 
cases are considered unexpected and handled as serious expedited cases by 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g. Other situations:

Medical or scientific judgment should be exercised by the investigator in 
deciding whether SAE reporting is appropriate in other situations, such as 
significant medical events that may jeopardize the participant or may require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious.

Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.
10.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safety throughout the active 
collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure. 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 72
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event
Recorded on the CRF
Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE
All
All
Nonserious AE
All
None
Exposure to the study 
intervention under study 
during pregnancy or 
breastfeeding
All AEs/SAEs associated 
with exposure during 
pregnancy or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.
All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure 
to the product under 
study to a 
non-participant (not 
involving EDP or EDB).
None. Exposure to a study 
non-participant is not 
collected on the CRF.
The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*
EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE 
Report Form. 
**  EDB is reported to Pfizer Safety using the CT SAE Report Form which would also include 
details of any SAE that might be associated with the EDB. 
*** Environmental or Occupational exposure: AEs or SAEs associated with occupational 
exposure are reported to Pfizer Safety using the CT SAE Report Form. 

When an AE or SAE occurs, it is the responsibility of the investigator to review 
all documentation (eg, hospital progress notes, laboratory reports, and 
diagnostic reports) related to the event.

The investigator will then record all relevant AE or SAE information in the 
CRF.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 73

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the 
medical records before submission to Pfizer Safety.

The investigator will attempt to establish a diagnosis of the event based on 
signs, symptoms, and/or other clinical information. Whenever possible, the 
diagnosis (not the individual signs/symptoms) will be documented as the AE or 
SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories: 

Mild: Asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.

Moderate: Minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, managing money, etc.

Severe: Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality

The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 74

A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration, will be considered and investigated.

The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.

For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality.

There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor.

The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.

If the investigator does not know whether or not the study intervention caused the
event, then the event will be handled as “related to study intervention” for 
reporting purposes, as defined by the sponsor. In addition, if the investigator 
determines that an SAE is associated with study procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow-Up of AEs and SAEs

The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically indicated or as 
requested by the sponsor, to elucidate the nature and/or causality of the AE or 
SAE as fully as possible. This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 75

If a participant dies during participation in the study or during a recognized 
follow-up period, the investigator will provide Pfizer Safety with a copy of any 
postmortem findings, including histopathology.

New or updated information will be recorded in the originally submitted 
documents.

The investigator will submit any updated SAE data to the sponsor within 24 
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via CT SAE Report Form

Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety.

In circumstances when the facsimile is not working, notification by telephone is 
acceptable with a copy of the CT SAE Report Form sent by overnight mail or 
courier service.

Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 76
10.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they agree to the following requirements during 
the intervention period and for at least 28 days after the last dose of study intervention, which
corresponds to the time needed to eliminate reproductive safety risk of the study 
intervention(s):

Refrain from donating sperm.
PLUS either:

Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and 
agree to remain abstinent.
OR

Must agree to use contraception/barrier as detailed below:

Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highly effective method of contraception as a condom may 
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently pregnant.

In addition to male condom use, a highly effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly 
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:

Is not a WOCBP (see definitions below in Section 10.4.3).
OR

Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), with low user dependency, as described below during the 
intervention period and for at least 28 days after the last dose of study intervention,
which corresponds to the time needed to eliminate any reproductive safety risk of the 
study intervention(s). The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 77
A WOCBP agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during 
this period. The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy. 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1. Premenopausal female with 1 of the following:

Documented hysterectomy;

Documented bilateral salpingectomy;

Documented bilateral oophorectomy.
For individuals with permanent infertility due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion 
should be applied to determining study entry.
Note: Documentation for any of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history interview. The method of documentation should be recorded in the 
participant’s medical record for the study.
2. Postmenopausal female.

A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition:

A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 

A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 78
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrollment.
10.4.4. Contraception Methods
Contraceptive use by men or women should be consistent with local availability/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency
1. Implantable progestogen-only hormone contraception associated with inhibition of 
ovulation.
2. Intrauterine device.
3. Intrauterine hormone-releasing system.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5. Vasectomized partner.

A vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highly effective method of contraception 
should be used. The spermatogenesis cycle is approximately 90 days.
6. Sexual abstinence.

Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 7 9
 
 
 
 
 
 
 
 
 
 
 
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 80
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments 
Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no signs of liver injury (as determined by elevations in 
transaminases) are termed “tolerators,” while those who show transient liver enzyme 
elevations but adapt are termed “adaptors.” In some participants, transaminase elevations are 
a harbinger of a more serious potential outcome. Participants who experience a transaminase 
elevation above 3 × ULN should be monitored more frequently to determine if they are 
“adaptors” or are “susceptible.”
Abnormal elevations in either AST OR ALT in addition to TBili that meet the criteria 
outlined below need to be evaluated for causality and should always be considered important 
medical events, even before all possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory abnormalities should halt/stop dosing and be evaluated for 
hepatic injury causality to definitively determine the etiology of the abnormal laboratory 
values:

Participants with AST/ALT and TBili baseline values within the normal range who 
subsequently present with AST OR ALT values >3 × ULN AND a TBili value 
>2 × ULN with no evidence of hemolysis and an alkaline phosphatase value 
<2 × ULN or not available.

For participants with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:

Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).

Preexisting values of TBili above the normal range: TBili level increased from 
baseline value by an amount of at least 1 × ULN or if the value reaches 
>3 × ULN (whichever is smaller).
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed 
individually based on clinical judgment; any case where uncertainty remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated for hepatic injury 
causality as soon as possible, preferably within 48 hours from awareness of the abnormal 
results. This evaluation should include laboratory tests, detailed history, and physical 
assessment. If on further evaluation the abnormal test result is repeated, the participant 


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 81
should be considered for discontinuation from the study drug and adequate, immediate, 
supportive measures taken.
In addition to repeating measurements of AST and ALT and TBili for suspected liver 
toxicity, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT-INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated 
product in prescription or over-the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family history, sexual history, travel history, history of contact 
with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (ultrasound, CT, MRI) (eg, biliary tract),
and collection of serum samples for acetaminophen/paracetamol drug and/or protein adduct 
levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DILI cases if no other reason 
for the LFT abnormalities has yet been found. Such potential DILI cases are to be 
reported as SAEs, irrespective of availability of all the results of the investigations 
performed to determine etiology of the LFT abnormalities.
A potential DILI case becomes a confirmed case only after all results of reasonable 
investigations have been received and have excluded an alternative etiology.


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 82
10.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs

Marked sinus bradycardia (rate <40 bpm) lasting minutes.

New PR interval prolongation >280 msec.

New prolongation of QTcF to >480 msec (absolute) or by 60 msec from 
baseline.

New-onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate <120 bpm.

New-onset type I second-degree (Wenckebach) AV block of >30 seconds’
duration.

Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings That May Qualify as SAEs

QTcF prolongation >500 msec.

New ST-T changes suggestive of myocardial ischemia.

New-onset left bundle branch block (QRS >120 msec).

New-onset right bundle branch block (QRS >120 msec).

Symptomatic bradycardia.

Asystole:

In awake, symptom-free participants in sinus rhythm, with documented 
periods of asystole ≥3.0 seconds or any escape rate <40 bpm, or with an 
escape rhythm that is below the AV node. 

In awake, symptom-free participants with atrial fibrillation and bradycardia 
with 1 or more pauses of at least 5 seconds or longer. 

Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.

Sustained supraventricular tachycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1 minute).


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 83

Ventricular rhythms >30 seconds’ duration, including idioventricular rhythm 
(heart rate <40 bpm), accelerated idioventricular rhythm (HR >40 bpm to
<100 bpm), and monomorphic/polymorphic ventricular tachycardia (HR 
>100 bpm [such as torsades de pointes]).

Type II second-degree (Mobitz II) AV block.

Complete (third-degree) heart block.
ECG Findings That Qualify as SAEs

Change in pattern suggestive of new myocardial infarction.

Sustained ventricular tachyarrhythmias (>30 seconds’ duration).

Second-or third-degree AV block requiring pacemaker placement.

Asystolic pauses requiring pacemaker placement.

Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion.

Ventricular fibrillation/flutter.

At the discretion of the investigator, any arrhythmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and Pfizer study team, and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 8 4
1 0. 8. A p pe n di x 8: A b bre vi ati o ns
T he f oll o wi n g is a list of a b bre viati o ns t hat ma y  be use d i n t he pr ot oc ol.
A b b re viati o n
Ter m
3 C L pr o
3 C -li ke pr otease
A bs
a bs ol ute
A D L
acti vities of dail y li vi n g
A E
a d verse e ve nt
A E SI
a d verse e ve nts of s pecial i nterest
A L T
ala ni ne a mi n otra nsferase
a P T T
acti vate d partial t hr o m b o plasti n ti me
A S T
as partate a mi n otra nsferase
A U C i nf
area u n der t he plas ma c o nce ntrati o n -ti me c ur ve fr o m ti me 0 
e xtra p olate d t o i nfi nite ti me
A U C last
area u n der t he plas ma c o nce ntrati o n-ti me c ur ve fr o m ti me 0 t o t he 
ti me of t he last q ua ntifia ble c o nce ntrati o n
A V
atri o ve ntric ular
B B S
Bi os peci me n Ba n ki n g S yste m
-h C G
beta -h u ma n c h ori o nic g o na d otr o pi n
BI D
t wice daily
B MI
b o d y  mass i n de x
B P
bl o o d press ure
b p m
beats per mi n ute
B U N
bl o o d urea nitr o ge n
C F R
C o de of Fe deral Re g ulati o ns
CI
c o nfi de nce i nter val
CI O M S
C o u ncil f or I nter nati o nal Or ga nizati o ns of Me dical Scie nces
C K
creati ne ki nase
C K D -E PI
c hr o nic ki d ne y disease e pi de mi ol o g y c olla b orati o n
C last
last q ua ntifia ble c o nce ntrati o n
C L / F
a p pare nt cleara nce
C ma x
ma xi m u m o bser ve d c o nce ntrati o n
C O 2
car b o n di o xi de ( bicar b o nate)
C O VI D -1 9
c or o na vir us disease 2 0 1 9
C R F
case re p ort f or m
C R O
c o ntract researc h or ga nizati o n
C R U
cli nical researc h u nit
C S R
cli nical st u d y re p ort
C T
cli nical trial; c o m p ute d t o m o gra p h y
C T M S
cli nical trial ma na ge me nt s yste m
C CI
C CI


P F -0 7 3 2 1 3 3 2 
Pr ot oc ol C 4 6 7 1 0 1 3 
Fi nal Pr ot oc ol, 2 3 J uly 2 0 2 1
P FI Z E R C O N FI D E N TI A L
Pa ge 8 5
A b b re viati o n
Ter m
C Y P
c yt oc hr o me P 4 5 0
D DI
dr u g -dr u g i nteracti o n 
DI LI
dr u g -i n d uce d li ver i nj ur y
D M C
data m o nit ori n g c o m mittee
E C
et hics c o m mittee
E C C
e mer ge nc y c o ntact car d
E C G
electr ocar di o gra m
e C R F
electr o nic case re p ort f or m
E D B
e x p os ure d uri n g breastfee di n g
E D P
e x p os ure d uri n g pre g na nc y
e G F R
esti mate d gl o mer ular filtrati o n rate
E M A
E ur o pea n Me dici nes A ge nc y
E U
E ur o pea n U ni o n
E u dra C T
E ur o pea n Cli nical Trials Data base
FI H
first-i n-h u ma n
F S H
f ollicle-sti m ulati n g h or m o ne
G C P
G o o d Cli nical Practice
G G T
ga m ma -gl uta m y l tra nsferase
G L P
G o o d L a b orat or y Practice
H B c A b
he patitis B c ore a nti b o d y
H Bs A b
he patitis B s urface a nti b o d y
H Bs A g 
he patitis B s urface a nti ge n
H C o V
h u ma n c or o na vir us
H C V
he patitis C vir us
H C V A b
he patitis C a nti b o d y
HI V
h u ma n i m m u n o deficie nc y vir us
H R
heart rate
H R T
h or m o ne re place me nt t hera p y
I B
i n vesti gat or’s br oc h ure
I C D
i nf or me d c o nse nt d oc u me nt
I C H
I nter nati o nal C o u ncil f or Har m o nisati o n
I D
i de ntificati o n
I ND
i n vesti gati o nal ne w dr u g 
I N R
i nter nati o nal n or malize d rati o
I P A L
I n vesti gati o nal Pr o d uct Acc o u nta bilit y  L o g
I Q M P
I nte grate d Q ualit y Ma na ge me nt Pla n
I RB
i nstit uti o nal re vie w b oar d
I V
i ntra ve n o us
k el
rate c o nsta nt f or ter mi nal p hase
L B B B
left b u n dle bra nc h bl oc k
C CI
C CI


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 86
Abbreviation
Term
LFT
liver function test
MAD
multiple ascending dose
MCH
mean corpuscular hemoglobin
MCHC
mean corpuscular hemoglobin concentration
MCV
mean corpuscular volume
MD
multiple dose
MERS
Middle East Respiratory Syndrome
MRI
magnetic resonance imaging
msec
millisecond
N/A
not applicable
NHP
non-human primates
NOAEL
no-observed-adverse-effect level
NSAE
non-serious adverse event
NYHA
New York Heart Association
PCR
polymerase chain reaction
PCRU
Pfizer clinical research unit
PD
pharmacodynamic(s)
PE
physical examination
PK
pharmacokinetic(s)
PR
pulse rate
PT
prothrombin time
PVC
premature ventricular contraction/complex
q12h
every 12 hours
QTc
corrected QT
QTcF
corrected QT (Fridericia method)
qual
qualitative
RBC
red blood cell
REML
the restricted (or residual, or reduced) maximum likelihood
RNA
ribonucleic acid
RR
respiratory rate
RT-PCR
reverse transcription polymerase chain reaction
SAD
single ascending dose
SAE
serious adverse event
SAP
statistical analysis plan
SARS-CoV-1
severe acute respiratory syndrome coronavirus 1
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
SCr
serum creatinine
SD
single dose
SmPC
Summary of Product Characteristics
SoA
schedule of activities
SOC
system organ class


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 87
Abbreviation
Term
SOP
standard operating procedure
SRSD
single reference safety document
SUSAR
suspected unexpected serious adverse reaction
t½
terminal half-life
T4
thyroxine
TBili
total bilirubin
TEAE
treatment emergent adverse event
THC
tetrahydrocannabinol
TID
three times daily
Tmax
time for Cmax
TSH
thyroid stimulating hormone
UGT
uridyl glycosyltransferase
ULN
upper limit of normal
US
United States
USPI
United States Package Insert
Vz/F
apparent volume of distribution
WBC
white blood cell
WHO
World Health Organization
WOCBP
woman/women of childbearing potential


PF-07321332 
Protocol C4671013 
Final Protocol, 23 July 2021
PFIZER CONFIDENTIAL
Page 88
11. REFERENCES
1
WHO Situation Report – 51. 11 March 2020. Available from: 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 
Accessed: 29 March 2020.
2
Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763-7.
3
Ritonavir SmPC. Available from: https://www.ema.europa.eu/en/documents/product-
information/norvir-epar-product-information_en.pdf.
4
Midazolam-ratiopharm® midazolam 2 mg/mL oral solution SmPC. Available from: 
https://www.ratiopharm.de/produkte/details/praeparate/praeparatedaten/detail/pzn-
11024506.html.
5
Midazolam USPI. Eatontown, NJ: West-Ward Pharmaceuticals Corp.; 2020. Available 
from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a833c24b-6dca-44d7-
a0d6-20012fa1ea77.
                                                

SAP_001.pdf: 
Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 1 of 18
PFIZER CONFIDENTIAL
Protocol C4671013
COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 
6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE 
THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR 
ON THE PHARMACOKINETICS OF MIDAZOLAM IN
HEALTHY PARTICIPANTS
Statistical Analysis Plan
(SAP)
Version:
1.0
SAP Author: 
                      
Date:    
30-AUG-2021
PPD
PPD


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 2 of 18
PFIZER CONFIDENTIAL
Revision History
Version
Date
Author(s)
Summary of Changes/Comments
Version 1.0
August 30, 2021
Not Applicable
NOTE: Italicized text within this document has been taken verbatim from the Protocol.
PPD


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 3 of 18
PFIZER CONFIDENTIAL
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................5
LIST OF FIGURES ...................................................................................................................5
APPENDICES ...........................................................................................................................5
1. AMENDMENTS FROM PREVIOUS VERSION(S) ...........................................................6
2. INTRODUCTION .................................................................................................................6
2.1. Study Design .............................................................................................................6
2.2. Study Objectives .......................................................................................................7
2.2.1. Primary Objective.........................................................................................7
2.2.2. Secondary Objectives ...................................................................................7
3. INTERIM ANALYSES, FINAL ANALYSES AND UNBLINDING..................................8
4. HYPOTHESES AND DECISION RULES...........................................................................8
4.1. Statistical Hypotheses ...............................................................................................8
4.2. Statistical Decision Rules..........................................................................................8
5. ANALYSIS SETS .................................................................................................................8
5.1. Pharmacokinetic (PK) Analysis Set ..........................................................................8
5.1.1. Concentration Analysis Set...........................................................................8
5.1.2. Parameter Analysis Set.................................................................................8
5.2. Pharmacodynamic Analysis Set................................................................................8
5.3. Safety Analysis Set....................................................................................................8
5.4. Other Analysis Sets ...................................................................................................8
5.5. Treatment Misallocations..........................................................................................9
5.6. Protocol Deviations...................................................................................................9
5.6.1. Deviations Assessed Prior to Randomization...............................................9
5.6.2. Deviations Assessed Post-Randomization....................................................9
6. ENDPOINTS AND COVARIATES .....................................................................................9
6.1. Efficacy Endpoint(s) .................................................................................................9
6.2. Safety Endpoints .......................................................................................................9
6.2.1. Adverse Events ...........................................................................................10
6.2.2. Laboratory Safety Tests..............................................................................10
CCI


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 4 of 18
PFIZER CONFIDENTIAL
6.2.3. Vital Signs Data..........................................................................................10
6.2.4. ECG Results................................................................................................11
6.2.5. Other Safety Data .......................................................................................11
6.3. Other Endpoints.......................................................................................................11
6.3.1. PK Endpoints..............................................................................................11
6.3.2. PD Endpoints..............................................................................................12
6.4. Covariates................................................................................................................12
7. HANDLING OF MISSING VALUES ................................................................................12
7.1. Concentrations Below the Limit of Quantification.................................................12
7.2. Deviations, Missing Concentrations and Anomalous Values .................................12
7.3. Pharmacokinetic Parameters ...................................................................................12
8. STATISTICAL METHODOLOGY AND STATISTICAL ANALYSES ..........................13
8.1. Statistical Methods ..................................................................................................13
8.2. Statistical Analyses .................................................................................................13
8.3. Safety Analysis........................................................................................................14
8.3.1. Treatment and Disposition of Participants .................................................15
8.3.2. Demographic and Clinical Examination Data............................................15
8.3.3. Discontinuation(s).......................................................................................15
8.3.4. Adverse Events ...........................................................................................15
8.3.5. Laboratory Data..........................................................................................15
8.3.6. Vital Signs Data..........................................................................................15
8.3.7. ECG Data....................................................................................................15
8.3.8. Other Safety Data .......................................................................................16
8.3.9. Concomitant Treatments.............................................................................16
8.3.10. COVID-19 Assessment Data....................................................................16
8.3.11. Screening and Other Special Purpose Data ..............................................16
9. REFERENCES ....................................................................................................................17
10. APPENDICES ...................................................................................................................18


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 5 of 18
PFIZER CONFIDENTIAL
LIST OF TABLES
Table 1.
Treatment Sequences..................................................................................7
Table 2.
PK Parameters to be Summarized Descriptively by Treatment ...............13
Table 3.
E14 QTcF Categorical Thresholds ...........................................................16
LIST OF FIGURES
None
APPENDICES
Appendix 1. SAS CODE FOR ANALYSES...........................................................................18


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 6 of 18
PFIZER CONFIDENTIAL
1. AMENDMENTS FROM PREVIOUS VERSION(S) 
None.
2. INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS-CoV-2 3CL protease that is
currently being developed as an oral treatment of COVID-19. Ritonavir is a strong CYP3A4
inhibitor being used to inhibit the metabolism of PF-07321332 in order to increase plasma
concentrations of PF-07321332 to values that are anticipated to be efficacious.
The purpose of the study is to evaluate the effect of PF-07321332/ritonavir and ritonavir on
the PK of midazolam, a CYP3A4 substrate, in healthy participants. Results from this study
will provide guidance for dosing recommendations with concomitant medications during
Phase 3 development and further establish the safety margins of PF-07321332/ritonavir.
2.1. Study Design
This is a Phase 1, open-label, 3-treatment, 6-sequence, 3-period crossover study to estimate
the effect of steady-state PF-07321332/ritonavir and ritonavir on the PK of midazolam in
healthy adult participants. The study will consist of 3 treatments: single oral dose of 2 mg
midazolam alone (Treatment A), multiple oral doses of 300 mg PF-07321332/100 mg
ritonavir in combination with a single oral dose of 2 mg midazolam (Treatment B), and
multiple oral doses of 100 mg ritonavir in combination with a single oral dose of 2 mg
midazolam (Treatment C). The treatment will consist of 6 treatment sequences shown in the
table below, with each participant receiving all 3 treatments, according to the assigned
sequence over 3 periods.
A total of approximately 12 healthy male and/or female participants will be enrolled into the
study to ensure at least 10 participants will complete the study. Participants who
discontinued from the study for non-safety reasons may be replaced at the sponsor’s
discretion in collaboration with the investigator.
Each enrolled participant will participate in 3 study periods to receive 3 different treatments:

Treatment A: Single oral dose of 2 mg midazolam, followed by serial PK sampling 
and 2-day washout (Treatment A period duration: Day 1 to Day 3)

Treatment B: 300 mg PF-07321332/100 mg ritonavir administered orally, q12h for 
9 doses: Day 1 morning to Day 5 morning. On Day 5, participants will receive a 
single oral dose of 2 mg midazolam administered with the Day 5 morning dose of 
PF-07321332/ritonavir, followed by serial PK sampling and a 7-day washout 
(Treatment B period duration: Day 1 to Day 12).


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 7 of 18
PFIZER CONFIDENTIAL
•
Treatment C: 100 mg ritonavir administered orally, q12h for 9 doses: Day 1 morning 
to Day 5 morning. On Day 5, participants will receive a single oral dose of 2 mg 
midazolam administered with the Day 5 morning dose of ritonavir, followed by serial 
PK sampling and a 7-day washout (Treatment C period duration: Day 1 to Day 12).
Participants will be randomly assigned to 1 of 6 sequences as in Table 1.
Table 1.
Treatment Sequences 
Sequence
Period 1
Period 2
Period 3
1 (2 participants)
Treatment A
Treatment B
Treatment C
2 (2 participants)
Treatment C
Treatment A
Treatment B
3 (2 participants)
Treatment B
Treatment C
Treatment A
4 (2 participants)
Treatment C
Treatment B
Treatment A
5 (2 participants)
Treatment B
Treatment A
Treatment C
6 (2 participants)
Treatment A
Treatment C
Treatment B
Participants will be discharged on Period 3, following completion of all assessments.
The total planned duration of participation, from the Screening visit to the last Follow-up 
phone call, is approximately 13 weeks.
2.2. Study Objectives
2.2.1. Primary Objective
•
To estimate the effect of PF-07321332/ritonavir on the PK of midazolam.
2.2.2. Secondary Objectives
•
To evaluate the safety and tolerability of PF-07321332/ritonavir in healthy 
participants in the absence and presence of midazolam.
•
To estimate the effect of ritonavir on the PK of midazolam.
•
To evaluate the effects of PF-07321332/ritonavir and ritonavir on additional PK 
parameters of midazolam in healthy participants.
 
CCI
CCI
CCI


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 8 of 18
PFIZER CONFIDENTIAL
 
 
4. HYPOTHESES AND DECISION RULES
4.1. Statistical Hypotheses
There are no statistical hypotheses.
4.2. Statistical Decision Rules
There are no statistical decision rules.
5. ANALYSIS SETS
5.1. Pharmacokinetic (PK) Analysis Set
5.1.1. Concentration Analysis Set
The PK concentration population is defined as all participants randomized and treated who 
have at least 1 concentration in at least 1 treatment period.  
5.1.2. Parameter Analysis Set
The PK parameter analysis population is defined as all participants randomized and treated 
who have at least 1 of the PK parameters of primary interest in at least 1 treatment period.
Should vomiting occur after co-administration of midazolam with PF-07321332/ritonavir, 
the resulting PK parameters from that participant from the corresponding period may be
excluded.
5.2. Pharmacodynamic Analysis Set
None.
5.3. Safety Analysis Set
All participants randomly assigned to study intervention and who take at least 1 dose of 
study intervention. Participants will be analyzed according to the product they actually 
received.
5.4. Other Analysis Sets
None.
CCI
CCI
CCI


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 9 of 18
PFIZER CONFIDENTIAL
5.5. Treatment Misallocations 
All analyses will be performed on an “as-treated” basis and will not include data from 
participants who are randomized but not treated.
If a participant takes a treatment that is not consistent with the treatment they are randomized 
to, for example takes a treatment out of sequence or takes the same treatment twice, then they 
will be reported under the treatment that they actually receive for all safety, and PK analyses,
where applicable.
5.6. Protocol Deviations
Participants who experience events that may affect their PK profile (eg lack of compliance 
with dosing) may be excluded from the PK analysis.  At the discretion of the 
pharmacokineticist a concentration value may also be excluded if the deviation in sampling 
time is of sufficient concern or if the concentration is anomalous for any other reason.
A full list of protocol deviations will be compiled and reviewed to identify major and minor 
deviations prior to database closure.
5.6.1. Deviations Assessed Prior to Randomization
At Screening, the investigator will assess participants against the inclusion and exclusion 
criteria as set out in Sections 5.1 and 5.2 of the protocol.
5.6.2. Deviations Assessed Post-Randomization
A full list of protocol deviations for the study report will be compiled prior to database 
closure.  Any significant deviation from the protocol will be reviewed prior to database 
closure and a decision taken regarding evaluation for each analysis population.
6. ENDPOINTS AND COVARIATES
6.1. Efficacy Endpoint(s)
None.
6.2. Safety Endpoints
The following data are considered in standard safety summaries (see protocol for collection 
days and list of parameters):

adverse events,

laboratory data,

vital signs,

ECG results.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 10 of 18
PFIZER CONFIDENTIAL
6.2.1. Adverse Events
An adverse event will be considered a Treatment-Emergent Adverse Event (TEAE) if the 
event started during the effective duration of treatment.  All events that start on or after the 
first dosing day and time/ start time, if collected, but before the last dose plus the lag time 
(28 days) will be flagged as TEAEs.  The algorithm will not consider any events that started 
prior to the first dose date.  Any events occurring following start of treatment or increasing in 
severity will be counted as treatment emergent.
Events that occur in a non-treatment period (for example, Washout or Follow-up) will be 
counted as treatment emergent and attributed to the previous treatment taken.
6.2.2. Laboratory Safety Tests
Safety laboratory tests will be performed as described in the protocol.
To determine if there are any clinically significant laboratory abnormalities, the 
haematological, clinical chemistry (serum) and urinalysis safety tests will be assessed against 
the criteria specified in the sponsor reporting standards.  The assessment will take into 
account whether each participant’s baseline test result is within or outside the laboratory 
reference range for the particular laboratory parameter.
Baseline is defined as the last planned predose measurement taken in each study period.
6.2.3. Vital Signs Data
Supine measurements will be taken at times detailed in the Schedule of Activities given in 
the protocol.
Baseline is the last predose recording in each study period.
The following vital signs endpoints will be determined:

The minimum systolic and diastolic blood pressures and the minimum and maximum 
pulse rates over all measurements taken postdose.

The maximum increase and maximum decrease from baseline over all measurements 
taken postdose for systolic and diastolic blood pressures.
The maximum increase from baseline will be calculated by firstly subtracting the baseline 
value from each postdose measurement to give the change from baseline.  The maximum of 
these values will then be selected, except in the case where a participant does not show an 
increase.  In such an instance, the minimum decrease should be taken.
Similarly, the maximum decrease from baseline will be determined by selecting the 
minimum value of the changes from baseline.  In cases where a participant does not show a 
decrease, the minimum increase should be taken.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 11 of 18
PFIZER CONFIDENTIAL
6.2.4. ECG Results
QT interval, QTc, PR, RR, QRS and heart rate will be recorded at each assessment time 
indicated in the Schedule of Activities given in the protocol.
If not supplied, QTcF will be derived using Fridericia’s heart rate correction formula:
QTcF = QT / (RR)1/3
where RR = 60/HR (if not provided)
The average of the triplicate measurements will be calculated prior to analyzing the data.  
Baseline will be defined as the average of the triplicate predose recordings in each study 
period. 
The maximum absolute value (postdose) and the maximum increase from baseline for QTcF, 
PR and QRS, over all measurements taken postdose, will be determined.
The maximum increase from baseline will be calculated by first subtracting the baseline 
value from each postdose measurement to give the change from baseline.  The maximum of 
these values will then be selected, except in the case where a participant does not show an 
increase.  In such an instance, the minimum decrease should be taken.
6.2.5. Other Safety Data
Additional safety data will be collected as described in the protocol and will be listed if 
collected in the sponsor’s database.
6.3. Other Endpoints
6.3.1. PK Endpoints
Blood samples will be taken according to the Schedule of Activities given in the protocol for 
PK analysis of midazolam following single dose administration with and without
PF-07321332/ritonavir or midazolam+ritonavir (as data permit).
The following PK parameters will be calculated for midazolam following single dose 
administration with and without PF-07321332/ritonavir or midazolam+ritonavir will be 
derived (if possible) from the concentration-time data using standard noncompartmental 
methods:
PK Parameter
Analysis Scale
Midazolam
PF-07321332
AUCinf*
ln
A, D
D
AUClast
ln
A, D
NA
AUClast
ln
A, D
D
Cmax
ln
A, D
D
Tmax
R
D
D
t1/2*
R
D
D
CL/F*
ln
D
D
CCI
CCI
CCI
CCI


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 12 of 18
PFIZER CONFIDENTIAL
Vz/F*
ln
D
D
Key:
A=analyzed using statistical model, D=displayed with descriptive statistics,
ln=natural-log transformed, NA=not applicable, R=raw (untransformed), *=if data 
permits
6.3.2. PD Endpoints
None.
6.4. Covariates
None.
7. HANDLING OF MISSING VALUES
For the analysis of safety endpoints, the sponsor data standard rules for imputation will be 
applied.
7.1. Concentrations Below the Limit of Quantification
In all data presentations (except listings), concentrations below the limit of quantification 
(BLQ) will be set to zero.  (In listings BLQ values will be reported as “<LLQ”, where LLQ 
will be replaced with the value for the lower limit of quantification). 
7.2. Deviations, Missing Concentrations and Anomalous Values
In summary tables and plots of median profiles, statistics will be calculated having set 
concentrations to missing if 1 of the following cases is true:
1. A concentration has been collected as ND (ie, not done) or NS (ie, no sample),
2. A deviation in sampling time is of sufficient concern or a concentration has been 
flagged anomalous by the pharmacokineticist.
Note that summary statistics will not be presented at a particular time point if more than
50% of the data are missing.
7.3. Pharmacokinetic Parameters
Actual PK sampling times will be used in the derivation of PK parameters.
If a PK parameter cannot be derived from a participant’s concentration data, the parameter 
will be coded as NC (ie, not calculated). (Note that NC values will not be generated beyond 
the day that a participant discontinues). 
In summary tables, statistics will be calculated by setting NC values to missing; and statistics 
will be presented for a particular treatment with ≥3 evaluable measurements.  For statistical 
analyses (ie, analysis of variance), PK parameters coded as NC will also be set to missing; 


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 13 of 18
PFIZER CONFIDENTIAL
and analyses will not be performed for a particular parameter if more than 50% of the data 
are NC.
If an individual participant has a known biased estimate of a PK parameter (due for example 
to an unexpected event such as vomiting before all the compound is adequately absorbed in 
the body), this will be footnoted in summary tables and will not be included in the calculation 
of summary statistics or statistical analyses.
8. STATISTICAL METHODOLOGY AND STATISTICAL ANALYSES
8.1. Statistical Methods
The interactive effect on PK parameters will be determined by constructing 90% confidence 
intervals around the estimated difference between the Test and Reference treatments using a 
mixed effects model based on natural log transformed data.  The mixed effects model will be 
implemented using SAS Proc Mixed, with REML estimation method and Kenward-Roger 
degrees of freedom algorithm.
8.2. Statistical Analyses
Natural log transformed AUCinf (if data permit), AUClast and Cmax of midazolam will be 
analyzed using a mixed effect model with sequence, period and treatment as fixed effects and 
participant within sequence as a random effect. Estimates of the adjusted mean differences
(Test-Reference) and corresponding 90% confidence intervals will be obtained from the
model. The adjusted mean differences and 90% confidence intervals for the differences will
be exponentiated to provide estimates of the ratio of adjusted geometric means
(Test/Reference) and 90% confidence intervals for the ratios. Midazolam alone is the
Reference treatment whilst midazolam + PF-07321332/ritonavir and midazolam + ritonavir
are the Test treatments.
Residuals from the model will be examined for normality and the presence of outliers via 
visual inspection of plots of residuals vs predicted values and normal probability plots of 
residuals but these will not be included in the clinical study report.  If there are major 
deviations from normality or outliers then the effect of these on the conclusions will be 
investigated through alternative transformations and/or analyses excluding outliers.  
Justification for any alternative to the planned analysis will be given in the report of the 
study.
Table 2.
PK Parameters to be Summarized Descriptively by Treatment
Parameter
Summary Statistics
AUCinf, 
AUClast, Cmax
N, arithmetic mean, median, cv%, standard deviation, minimum, 
maximum, geometric mean and geometric cv%.
Tmax
N, median, minimum, maximum.
t1/2, CL/F, 
Vz/F
N, arithmetic mean, median, cv%, standard deviation, minimum, 
maximum.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 14 of 18
PFIZER CONFIDENTIAL
Box and whisker plots for individual participant parameters (AUCinf, AUClast and Cmax) will 
be presented by treatment and overlaid with geometric means.
Supporting data from the estimation of t½ and AUCinf will be listed by analyte and treatment: 
terminal phase rate constant (kel); goodness of fit statistic from the log-linear regression (r2); 
the percent of AUCinf based on extrapolation (AUCextrap%); and the first, last, and number of 
time points used in the estimation of kel.  This data may be included in the clinical study 
report.
Presentations for midazolam and PF-07321332 concentrations will include:

A listing of all concentrations sorted by participant ID, period and nominal time 
postdose.  The concentration listing will also include the actual times.  Deviations 
from the nominal time will be given in a separate listing.

A summary of concentrations by treatment and nominal time postdose, where the set 
of statistics will include n, mean, median, standard deviation, coefficient of variation 
(cv), minimum, maximum and the number of concentrations above the lower limit of 
quantification.

Median concentrations time plots (on both linear and semi-log scales) against 
nominal time postdose by treatment (all treatments on the same plot per scale, based 
on the summary of concentrations by treatment and time postdose).

Mean concentrations time plots (on both linear and semi-log scales) against nominal 
time postdose by treatment (all treatments on the same plot per scale, based on the 
summary of concentrations by treatment and time postdose).

Individual concentration time plots by treatment (on both linear and semi-log scales) 
against actual time postdose (there will be separate spaghetti plots for each treatment 
per scale).

Individual concentration time plots by participant (on both linear and semi-log scales) 
against actual time postdose [there will be separate plots for each participant
(containing all treatments) per scale].
For summary statistics, median and mean plots by sampling time, the nominal PK sampling 
time will be used, for individual participant plots by time, the actual PK sampling time will 
be used.
8.3. Safety Analysis
A set of summary tables split by treatment will be produced to evaluate any potential risk 
associated with the safety and toleration of administering midazolam following single dose 
administration with and without PF-07321332/ritonavir or ritonavir.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 15 of 18
PFIZER CONFIDENTIAL
8.3.1. Treatment and Disposition of Participants
Participant evaluation groups will show end of study participant disposition and will show 
which participants were analyzed for pharmacokinetics, as well as for safety (adverse events 
and laboratory data).  Frequency counts will be supplied for participant discontinuation(s) by 
treatment.
Data will be reported in accordance with the sponsor reporting standards.
8.3.2. Demographic and Clinical Examination Data
A break down of demographic data will be provided for age, race, weight, body mass index, 
and height.  Each will be summarized by sex at birth and ‘All Participants’ in accordance 
with the sponsor reporting standards.
8.3.3. Discontinuation(s)
Participant discontinuations, temporary discontinuations or dose reductions due to adverse 
events will be detailed and summarized by treatment.
Data will be reported in accordance with the sponsor reporting standards.
8.3.4. Adverse Events
Adverse events will be reported in accordance with the sponsor reporting standards by 
treatment.
8.3.5. Laboratory Data
Laboratory data will be listed and summarized by treatment in accordance with the sponsor 
reporting standards.  Baseline is as defined in Section 6.2.2.
8.3.6. Vital Signs Data
Vital Signs data will be summarized and listed in accordance with the sponsor reporting
standards.
8.3.7. ECG Data
Baseline and changes from baseline in PR, QT, QRS, heart rate and QTcF will be 
summarized by treatment and time postdose.  Baseline is as defined in Section 6.2.4.
ECG endpoints and changes from baseline (QTcF, PR, QRS), over all measurements taken 
postdose, will also be summarized descriptively by treatment using categories as defined in 
the Criteria for Safety Values of Potential Clinical Concern appendix of the protocol and for 
QTc values corresponding to ICH E141 thresholds below.  Numbers and percentages of 
participants meeting the categorical criteria will be provided and individual values listed in 
the study report.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 16 of 18
PFIZER CONFIDENTIAL
Table 3.
E14 QTcF Categorical Thresholds
Parameter
Criterion
QTcF (msec)
450≤ value <480
480≤ value <500
≥500
QTcF (msec) increase from 
baseline
30≤ change <60
change ≥60
These data will be listed in accordance with the sponsor reporting standards.
8.3.8. Other Safety Data
None.
8.3.9. Concomitant Treatments
All concomitant medication(s) as well as non-drug treatment(s) will be provided in the 
listings.
8.3.10. COVID-19 Assessment Data
Participants will be tested for SARS-COVID-19 infection by RT-PCR prior to being admitted 
to the clinic for confinement and a subsequent COVID-19 test will be performed after 4 days 
(ie, upon completion of 4 x 24 hours in house), or if they develop COVID-19 like symptoms. 
Additional testing may be required by local regulations or by the Principal Investigator.
These data will be listed in accordance with the sponsor reporting standards.
8.3.11. Screening and Other Special Purpose Data
Prior medication(s) and non-drug treatment(s), serum FSH concentrations, urine drug screen, 
serum or urine B-hCG for all females of childbearing potential, TSH and Free T4, Prep D1, 
HIV, HBsAg, HBsAb, HBcAb, and HCVAb will be obtained at Screening.
If these data are brought in-house, then they will be listed.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 17 of 18
PFIZER CONFIDENTIAL
9. REFERENCES
1.
ICH E14 - The clinical evaluation of QT/QTc interval prolongation and proarrhythmic 
potential for non-antiarrhythmic drugs. CHMP/ICH/2/04.


Protocol C4671013 (PF-07321332) Statistical Analysis Plan
Page 18 of 18
PFIZER CONFIDENTIAL
10. APPENDICES
Appendix 1. SAS CODE FOR ANALYSES
An example of the PROC MIXED code is provided below:
proc mixed data=tab.pk;
class seq period trt participant;
model l&var=seq period trt/ ddfm=KR;
random participant(seq) /participant=participant(seq);
lsmeans trt;
estimate 'B vs A' trt -1  1  0/cl alpha=0.1;
            estimate 'C vs A' trt -1  0  1/cl alpha=0.1;
ods 'Estimates' out=est&var;
ods 'lsmeans' out=ls&var;
ods 'covparms' out=cov&var;
ods 'tests3' out=tst&var;
run;
/* Letter assignments for treatments (trt) within the estimate statement above are as follows;
A = Midazolam alone (Reference);
B = Midazolam + PF-07321332/ritonavir (Test)
C = Midazolam + ritonavir (test) */;